Any feedback?
Information on EC 1.1.1.41 - isocitrate dehydrogenase (NAD+)
for references in articles please use BRENDA:EC1.1.1.41Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
1.1.1.41 isocitrate dehydrogenase (NAD+)IUBMB Comments
Requires Mn2+ or Mg2+ for activity. Unlike EC 1.1.1.42, isocitrate dehydrogenase (NADP+), oxalosuccinate cannot be used as a substrate. In eukaryotes, isocitrate dehydrogenase exists in two forms: an NAD+-linked enzyme found only in mitochondria and displaying allosteric properties, and a non-allosteric, NADP+-linked enzyme that is found in both mitochondria and cytoplasm . The enzyme from some species can also use NADP+ but much more slowly .
Specify your search results
Word Map
- 1.1.1.41
- glioma
- glioblastoma
- malate
- succinate
-
tricarboxylic
- glucose-6-phosphate
-
malic
- myeloid
- dehydrogenases
- leukemia
-
idh-mutant
- tca
- astrocytomas
- 2-hydroxyglutarate
- nadp+
- aconitase
- oligodendrogliomas
-
oncometabolite
-
nadp+-dependent
-
resect
- alpha-ketoglutarate
-
krebs
- glyoxylate
-
codeletion
-
preoperative
- 2-oxoglutarate
-
radiotherapy
-
lower-grade
- 6-phosphogluconate
- lgg
-
progression-free
-
anaplastic
-
high-grade
- temozolomide
-
gliomagenesis
- chondrosarcoma
-
nadp-linked
-
karnofsky
- fumarase
-
radiomics
-
contrast-enhanced
-
oligodendroglial
-
o6-methylguanine-dna
-
neuro-oncology
-
flair
-
pilocytic
-
ten-eleven
- diagnostics
- oligoastrocytomas
-
thoracis
- semitendinosus
The expected taxonomic range for this enzyme is: Bacteria, Archaea, Eukaryota
Synonyms
isocitrate dehydrogenase, isocitrate dehydrogenase 2, isocitric dehydrogenase, nad-dependent isocitrate dehydrogenase, idh3a, nad-idh, nad-isocitrate dehydrogenase, nad-icdh, nad+-dependent isocitrate dehydrogenase, nad-linked isocitrate dehydrogenase, 
more
top
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
beta-ketoglutaric-isocitric carboxylase
-
-
-
-
IDH1
-
-
-
-
isocitric acid dehydrogenase
-
-
-
-
isocitric dehydrogenase
-
-
-
-
NAD dependent isocitrate dehydrogenase
-
-
-
-
NAD isocitrate dehydrogenase
-
-
-
-
NAD isocitric dehydrogenase
-
-
-
-
NAD+-specific ICDH
-
-
-
-
NAD-linked isocitrate dehydrogenase
-
-
-
-
NAD-specific isocitrate dehydrogenase
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
redox reaction
-
-
-
-
oxidation
-
-
-
-
reduction
-
-
-
-
oxidative decarboxylation
-
-
-
-
reductive carboxylation
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PATHWAY SOURCE
PATHWAYS
BRENDA
KEGG
-
-, -, -
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYSTEMATIC NAME
IUBMB Comments
isocitrate:NAD+ oxidoreductase (decarboxylating)
Requires Mn2+ or Mg2+ for activity. Unlike EC 1.1.1.42, isocitrate dehydrogenase (NADP+), oxalosuccinate cannot be used as a substrate. In eukaryotes, isocitrate dehydrogenase exists in two forms: an NAD+-linked enzyme found only in mitochondria and displaying allosteric properties, and a non-allosteric, NADP+-linked enzyme that is found in both mitochondria and cytoplasm [7]. The enzyme from some species can also use NADP+ but much more slowly [9].
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
9001-58-5
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
COFACTOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Adenocarcinoma
Chronic nickel (II) exposure induces the stemness properties of cancer cells through repressing isocitrate dehydrogenase (IDH1).
Adenocarcinoma
Inactivation of metabolic enzymes by photo-treatment with zinc meta N-methylpyridylporphyrin.
Adenocarcinoma
Influence of HSP27 and steroid receptor status on provera sensitivity, DNA-ploidy and survival of females with endometrial cancer.
Adenocarcinoma of Lung
Effect of IDH3a on glucose uptake in lung adenocarcinoma: A pilot study based on [18 F]FDG.
alpha-Thalassemia
In Vivo Molecular Profiling of Human Glioma : Cross-Sectional Observational Study Using Dynamic Susceptibility Contrast Magnetic Resonance Perfusion Imaging.
alpha-Thalassemia
Main genetic differences in high-grade gliomas may present different MR imaging and MR spectroscopy correlates.
Arthritis
Oxidative state and oxidative metabolism of the heart from rats with adjuvant-induced arthritis.
Asthenozoospermia
Mobile phones electromagnetic radiation and NAD+-dependent isocitrate dehydrogenase as a mitochondrial marker in asthenozoospermia.
Astrocytoma
A juvenile case of epilepsy-associated, isocitrate dehydrogenase wild-type/histone 3 wild-type diffuse glioma with a rare BRAF A598T mutation.
Astrocytoma
A radiomics nomogram may improve the prediction of IDH genotype for astrocytoma before surgery.
Astrocytoma
Analysis of Cellular Feature Differences of Astrocytomas with Distinct Mutational Profiles Using Digitized Histopathology Images.
Astrocytoma
Analysis of Mutant Isocitrate Dehydrogenase 1 Immunoexpression, Ki-67 and Programmed Death Ligand 1 in Diffuse Astrocytic Tumours : Study of Single Center in Bandung, Indonesia.
Astrocytoma
Awake Craniotomy and Resection of a Left Frontal High-Grade Glioma: 2-Dimensional Operative Video.
Astrocytoma
Chaperonin-containing tailless complex polypeptide 1 subunit 6A correlates with increased World Health Organization grade, less isocitrate dehydrogenase mutation, and deteriorative survival of astrocytoma patients.
Astrocytoma
Chromatin-regulating genes are associated with postoperative prognosis and isocitrate dehydrogenase mutation in astrocytoma.
Astrocytoma
Clinical Imaging for Diagnostic Challenges in the Management of Gliomas: A Review.
Astrocytoma
Clinical significance of the 2016 WHO classification in Japanese patients with gliomas.
Astrocytoma
Comparing the value of DKI and DTI in detecting isocitrate dehydrogenase genotype of astrocytomas.
Astrocytoma
Detection of 2-Hydroxyglutarate in Formalin-Fixed Paraffin-Embedded Glioma Specimens by Gas Chromatography/Mass Spectrometry.
Astrocytoma
Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues.
Astrocytoma
Diagnostic Utility of Oncomine Comprehensive Assay v3 in Differentiating Between Isocitrate Dehydrogenase (IDH)-mutated Grade II-III Astrocytoma and Oligodendroglioma.
Astrocytoma
DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Astrocytoma
DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas.
Astrocytoma
Finding of IDH1 R132H mutation in histologically non-neoplastic glial tissue changes surgical strategies, a case report.
Astrocytoma
Grading of Diffuse Astrocytic Gliomas: A Review of Studies Before and After the Advent of IDH Testing.
Astrocytoma
Histone 3 Lysine 9 Trimethylation Is Differentially Associated With Isocitrate Dehydrogenase Mutations in Oligodendrogliomas and High-Grade Astrocytomas.
Astrocytoma
Huge heterogeneity in survival in a subset of adult patients with resected, wild-type isocitrate dehydrogenase status, WHO grade II astrocytomas.
Astrocytoma
IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations.
Astrocytoma
IDH mutation status and the development of venous thromboembolism in astrocytoma patients.
Astrocytoma
IDH mutations associated impact on related cancer epidemiology and subsequent effect toward HIF-1?.
Astrocytoma
IDH-Mutant Astrocytoma With Chromosome 19q13 Deletion Manifesting as an Oligodendroglioma-Like Morphology.
Astrocytoma
Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management.
Astrocytoma
Integrated genomic and transcriptomic analysis suggests KRT18 mutation and MTAP are key genetic alterations related to the prognosis between astrocytoma and glioblastoma.
Astrocytoma
KIAA1549-BRAF Fusions and IDH Mutations Can Coexist in Diffuse Gliomas of Adults.
Astrocytoma
Low-Grade Astrocytoma Mutations in IDH1, P53, and ATRX Cooperate to Block Differentiation of Human Neural Stem Cells via Repression of SOX2.
Astrocytoma
Magnetic resonance imaging criteria for prediction of isocitrate dehydrogenase (IDH) mutation status in patients with grade II-III astrocytoma and oligodendroglioma.
Astrocytoma
Management of diffuse low-grade gliomas in adults - use of molecular diagnostics.
Astrocytoma
MiR-16-5p is frequently down-regulated in astrocytic gliomas and modulates glioma cell proliferation, apoptosis and response to cytotoxic therapy.
Astrocytoma
Mismatch repair proteins PMS2 and MLH1 can further refine molecular stratification of IDH-mutant lower grade astrocytomas.
Astrocytoma
Mitotic Index Thresholds Do Not Predict Clinical Outcome for IDH-Mutant Astrocytoma.
Astrocytoma
Molecular diagnostics of gliomas using next generation sequencing of a glioma-tailored gene panel.
Astrocytoma
Mutant IDH sensitizes gliomas to endoplasmic reticulum stress and triggers apoptosis by MicroRNA183-mediated inhibition of Semaphorin 3E.
Astrocytoma
Mutant IDH1 cooperates with ATRX loss to drive the alternative lengthening of telomere (ALT) phenotype in glioma.
Astrocytoma
Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in IDH-Mutant Lower Grade Gliomas.
Astrocytoma
Neuronal-astrocyte metabolic interactions: understanding the transition into abnormal astrocytoma metabolism.
Astrocytoma
Non-measurable speckled contrast-enhancing lesions appearing during course of disease are associated with IDH mutation in high-grade astrocytoma patients.
Astrocytoma
Noninvasively detecting Isocitrate dehydrogenase 1 gene status in astrocytoma by dynamic susceptibility contrast MRI.
Astrocytoma
Outcomes of salvage fractionated re-irradiation combined with bevacizumab for recurrent high-grade gliomas that progressed after bevacizumab treatment*.
Astrocytoma
Polysomy is associated with poor outcome in 1p19q co-deleted oligodendroglial tumors.
Astrocytoma
Pre-operative Neurocognitive Function Was More Susceptible to Decline in Isocitrate Dehydrogenase Wild-Type Subgroups of Lower-Grade Glioma Patients.
Astrocytoma
Quantitative Proteomics Reveals Fundamental Regulatory Differences in Oncogenic HRAS and Isocitrate Dehydrogenase (IDH1) Driven Astrocytoma.
Astrocytoma
Reproducible imaging-based prediction of molecular subtype and risk stratification of gliomas across different experience levels using a structured reporting system.
Astrocytoma
Ribosomal Protein S27/Metallopanstimulin-1 (RPS27) in Glioma-A New Disease Biomarker?
Astrocytoma
Somatostatin receptor 2A in gliomas: Association with oligodendrogliomas and favourable outcome.
Astrocytoma
Surgery of Insular Diffuse Gliomas-Part 1: Transcortical Awake Resection Is Safe and Independently Improves Overall Survival.
Astrocytoma
Survival, Prognostic Factors, and Volumetric Analysis of Extent of Resection for Anaplastic Gliomas.
Astrocytoma
T2 mapping of the peritumoral infiltration zone of glioblastoma and anaplastic astrocytoma.
Astrocytoma
T2-FLAIR mismatch in isocitrate dehydrogenase mutant astrocytomas: Variability and evolution.
Astrocytoma
Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.
Astrocytoma
Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.
Astrocytoma
Temozolomide radiochemotherapy for high-grade glioma patients with hemodialysis: a case series of 7 patients.
Astrocytoma
The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas.
Astrocytoma
The Histopathologic and Radiologic Features of T2-FLAIR Mismatch Sign in IDH-Mutant 1p/19q Non-codeleted Astrocytomas.
Astrocytoma
The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis.
Astrocytoma
The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade II Cerebral Gliomas in Adults: Version 2019.01.
Astrocytoma
The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade III Cerebral Gliomas in Adults: Version 2019.01.
Astrocytoma
The presence of TIM-3 positive cells in WHO grade III and IV astrocytic gliomas correlates with isocitrate dehydrogenase mutation status.
Astrocytoma
The T2-FLAIR Mismatch Sign as an Imaging Marker for Non-Enhancing IDH-mutant, 1p/19q-intact Lower Grade Glioma: A Validation Study.
Astrocytoma
TP53 Mutation and Extraneural Metastasis of Glioblastoma: Insights From an Institutional Experience and Comprehensive Literature Review.
Astrocytoma
Treatment of adult brainstem glioma with combined antiangiogenic therapy: a case report and literature review.
Astrocytoma
Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
Astrocytoma
WT1 in astrocytomas: Comprehensive evaluation of immunohistochemical expression and its potential utility in different histological grades.
Ataxia Telangiectasia
ATM mutations improve radio-sensitivity in wild-type isocitrate dehydrogenase-associated high-grade glioma: retrospective analysis using next-generation sequencing data.
Biliary Tract Diseases
[Isocitrate dehydrogenase activity in liver and biliary tract diseases as an indicator of liver cell necrosis]
Biliary Tract Neoplasms
Recent Advances in Targeted Therapies for Advanced Gastrointestinal Malignancies.
Blindness
A novel variant in IDH3A identified in a case with Leber congenital amaurosis accompanied by macular pseudocoloboma.
Bone Marrow Failure Disorders
JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition.
Brain Diseases
Homozygous mutation, p.Pro304His, in IDH3A, encoding isocitrate dehydrogenase subunit is associated with severe encephalopathy in infancy.
Brain Injuries, Traumatic
Smooth, an hnRNP-L Homolog, Might Decrease Mitochondrial Metabolism by Post-Transcriptional Regulation of Isocitrate Dehydrogenase (Idh) and Other Metabolic Genes in the Sub-Acute Phase of Traumatic Brain Injury.
Brain Neoplasms
A comprehensive review of available omics data resources and molecular profiling for precision glioma studies.
Brain Neoplasms
Absolute quantification of 2-hydroxyglutarate on tissue by matrix-assisted laser desorption/ionization mass spectrometry imaging for rapid and precise identification of isocitrate dehydrogenase mutations in human glioma.
Brain Neoplasms
Application of denaturing capillary electrophoresis for the detection of prognostic mutations in isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 genes in brain tumors.
Brain Neoplasms
Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma.
Brain Neoplasms
Association of The IDH1 C.395G>A (R132H) Mutation with Histological Type in Malay Brain Tumors
Brain Neoplasms
Classification of brain tumor isocitrate dehydrogenase status using MRI and deep learning.
Brain Neoplasms
Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations.
Brain Neoplasms
Glioma Grading and Determination of IDH Mutation Status and ATRX loss by DCE and ASL Perfusion.
Brain Neoplasms
Human glioblastoma arises from subventricular zone cells with low-level driver mutations.
Brain Neoplasms
Imaging Findings of New Entities and Patterns in Brain Tumor: Isocitrate Dehydrogenase Mutant, Isocitrate Dehydrogenase Wild-Type, Codeletion, and MGMT Methylation.
Brain Neoplasms
Improved Brain Tumor Classification by Sodium MR Imaging: Prediction of IDH Mutation Status and Tumor Progression.
Brain Neoplasms
Intracerebral Distribution of the Oncometabolite d-2-Hydroxyglutarate in Mice Bearing Mutant Isocitrate Dehydrogenase Brain Tumors: Implications for Tumorigenesis.
Brain Neoplasms
Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas.
Brain Neoplasms
Isocitric dehydrogenase of the cerebrospinal fluid in brain tumours and meningitis.
Brain Neoplasms
Liquid biopsies for diagnosing and monitoring primary tumors of the central nervous system.
Brain Neoplasms
Next Generation Sequencing-Based Transcriptome Predicts Bevacizumab Efficacy in Combination with Temozolomide in Glioblastoma.
Brain Neoplasms
Oncometabolite D-2-Hydroxyglurate Directly Induces Epithelial-Mesenchymal Transition and is Associated with Distant Metastasis in Colorectal Cancer.
Brain Neoplasms
Pharmacotranscriptomic Analysis Reveals Novel Drugs and Gene Networks Regulating Ferroptosis in Cancer.
Brain Neoplasms
Radiomics derived from amino-acid PET and conventional MRI in patients with high-grade gliomas.
Brain Neoplasms
Recent aspects of classification and epidemiology of epilepsy-associated tumors.
Brain Neoplasms
Remarkable response of a patient with secondary glioblastoma to a histone deacetylase inhibitor.
Brain Neoplasms
Transcriptional alterations in glioma result primarily from DNA methylation-independent mechanisms.
Brain Neoplasms
Warburg tumours and the mechanisms of mitochondrial tumour suppressor genes. Barking up the right tree?
Brain Neoplasms
World Cancer Day 2021 - Perspectives in Pediatric and Adult Neuro-Oncology.
Breast Neoplasms
Analysis of Isocitrate Dehydrogenase -2 (IDH-2) Activity in Human Serum as a Biomarker in Chemotherapy Patients of Breast Carcinoma: A Case-Control Study.
Breast Neoplasms
Human Phosphoglycerate Dehydrogenase Produces the Oncometabolite d-2-Hydroxyglutarate.
Breast Neoplasms
Isocitrate dehydrogenase 1-snail axis dysfunction significantly correlates with breast cancer prognosis and regulates cell invasion ability.
Breast Neoplasms
Proteomic analysis of ductal carcinoma of the breast using laser capture microdissection, LC-MS, and 16O/18O isotopic labeling.
Breast Neoplasms
Serine biosynthesis is a metabolic vulnerability in IDH2-driven breast cancer progression.
Breast Neoplasms
The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer.
Breast Neoplasms
[Biochemical behavior of pyruvate kinase, LDH, isocitrate dehydrogenase and malate dehydrogenase in breast carcinomas]
Carcinogenesis
A high-throughput analysis of the IDH1(R132H) protein expression in pituitary adenomas.
Carcinogenesis
Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma.
Carcinogenesis
Identification of New Biomarkers Associated With IDH Mutation and Prognosis in Astrocytic Tumors Using NanoString nCounter Analysis System.
Carcinogenesis
Intracerebral Distribution of the Oncometabolite d-2-Hydroxyglutarate in Mice Bearing Mutant Isocitrate Dehydrogenase Brain Tumors: Implications for Tumorigenesis.
Carcinogenesis
Isocitrate dehydrogenase 1R132H mutation in microglia/macrophages in gliomas: Indication of a significant role of microglia/macrophages in glial tumorigenesis.
Carcinogenesis
Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.
Carcinogenesis
Isocitrate dehydrogenase mutations in chondrosarcoma: the crossroads between cellular metabolism and oncogenesis.
Carcinogenesis
Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition.
Carcinogenesis
Multifocal Renal Cell Carcinomas With Somatic IDH2 Mutation: Report of a Previously Undescribed Neoplasm.
Carcinogenesis
Oncometabolite D-2-Hydroxyglurate Directly Induces Epithelial-Mesenchymal Transition and is Associated with Distant Metastasis in Colorectal Cancer.
Carcinogenesis
Suppression of tumorigenesis in mitochondrial NADP(+)-dependent isocitrate dehydrogenase knock-out mice.
Carcinogenesis
Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas.
Carcinogenesis
The role of NAD(+)-dependent isocitrate dehydrogenase 3 subunit ? in AFB1 induced liver lesion.
Carcinogenesis
Toward an improved definition of the genetic and tumor spectrum associated with SDH germ-line mutations.
Carcinogenesis
Tumor M2-PK and glutaminolytic enzymes in the metabolic shift of tumor cells.
Carcinogenesis
Wild-type IDH2 contributes to Epstein-Barr virus-dependent metabolic alterations and tumorigenesis.
Carcinogenesis
[The role of lipid metabolism disorders, atypical isoforms of protein kinase C, and mutational status of cytosolic and mitochondrial forms of isocitrate dehydrogenase in carcinogenesis of glial tumors].
Carcinoma
Breaking the ritual metabolic cycle in order to save acetyl CoA: A potential role for mitochondrial humanin in T2 bladder cancer aggressiveness.
Carcinoma
Diphosphopyridine nucleotide specific isocitric dehydrogenase of mammalian mitochondria. II. Kinetic properties of the enzyme of the Ehrlich ascites carcinoma.
Carcinoma
Elucidation of the TMab-6 Monoclonal Antibody Epitope Against Telomerase Reverse Transcriptase.
Carcinoma
Flow-cytometric determination of dehydrogenase activities in primary human gastrointestinal tumor cell lines.
Carcinoma
Immunohistochemical Detection and Molecular Characterization of IDH-mutant Sinonasal Undifferentiated Carcinomas.
Carcinoma
Isocitrate dehydrogenase 2 contributes to radiation resistance of oesophageal squamous cell carcinoma via regulating mitochondrial function and ROS/pAKT signalling.
Carcinoma
Isocitrate dehydrogenase gene mutations and 2-hydroxyglutarate accumulation in esophageal squamous cell carcinoma.
Carcinoma
Isozymes of NADP-linked isocitric dehydrogenase in psoriasis and human basal cell carcinoma.
Carcinoma
Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?
Carcinoma
NAD-dependent isocitrate dehydrogenase as a novel target of tributyltin in human embryonic carcinoma cells.
Carcinoma
Prognostic and diagnostic potential of isocitrate dehydrogenase 1 in esophageal squamous cell carcinoma.
Carcinoma
Serum enzymes in disease V. Isocitric dehydrogenase, malic dehydrogenase, and glycolytic enzymes in patients with carcinoma of the breast.
Carcinoma
Squamous cell carcinoma arising in dedifferentiated chondrosarcoma proved by isocitrate dehydrogenase mutation analysis.
Carcinoma
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Carcinoma
The clinical significance of isocitrate dehydrogenase 2 in esophageal squamous cell carcinoma.
Carcinoma
Tributyltin induces G2/M cell cycle arrest via NAD(+)-dependent isocitrate dehydrogenase in human embryonic carcinoma cells.
Carcinoma
Tributyltin induces mitochondrial fission through NAD-IDH dependent mitofusin degradation in human embryonic carcinoma cells.
Carcinoma
[Histoenzymatic studies of carcinoma of the cervix (lactic dehydrogenase, malic dehydrogenase, isocitric dehydrogenase and succinic dehydrogenase)]
Carcinoma, Basal Cell
Isozymes of NADP-linked isocitric dehydrogenase in psoriasis and human basal cell carcinoma.
Carcinoma, Ehrlich Tumor
Enzyme activities of six different dehydrogenases in Ehrlich ascites cells measured by flow cytometry.
Carcinoma, Hepatocellular
A pilot study on the screening of primary hepatocellular carcinoma in selected high risk groups in the population using multiple tumour markers.
Carcinoma, Hepatocellular
Chemopreventive efficacy of selenium against N-nitrosodiethylamine-induced hepatoma in albino rats.
Carcinoma, Hepatocellular
Genetic variations in IDH gene as prognosis predictors in TACE-treated hepatocellular carcinoma patients.
Carcinoma, Hepatocellular
High expression of 5-hydroxymethylcytosine and isocitrate dehydrogenase 2 is associated with favorable prognosis after curative resection of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Isocitrate Dehydrogenase 2 Suppresses the Invasion of Hepatocellular Carcinoma Cells via Matrix Metalloproteinase 9.
Carcinoma, Hepatocellular
Isocitrate dehydrogenase 3A, a rate-limiting enzyme of the TCA cycle, promotes hepatocellular carcinoma migration and invasion through regulation of MTA1, a core component of the NuRD complex.
Carcinoma, Squamous Cell
Comparative proteomic analysis of esophageal squamous cell carcinoma.
Carcinoma, Squamous Cell
Elucidation of the TMab-6 Monoclonal Antibody Epitope Against Telomerase Reverse Transcriptase.
Carcinoma, Squamous Cell
Squamous cell carcinoma arising in dedifferentiated chondrosarcoma proved by isocitrate dehydrogenase mutation analysis.
Carcinoma, Squamous Cell
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Cardiotoxicity
A possible mechanism of adriamycin cardiotoxicity. Inhibition of NADP-linked isocitrate dehydrogenase.
Cataract
[Malate dehydrogenase and TPN-specific isocitrate dehydrogenase in human cataract lenses]
Central Nervous System Neoplasms
CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Central Nervous System Neoplasms
Is chemotherapy alone an option as initial treatment for low-grade oligodendrogliomas?
Chemical and Drug Induced Liver Injury
[Activity of liver mitochondrial NAD+-dependent dehydrogenases of the krebs cycle in rats with acetaminophen-induced hepatitis developed under conditions of alimentary protein deficiency].
Cholangiocarcinoma
Anatomical, histomorphological and molecular classification of cholangiocarcinoma.
Cholangiocarcinoma
Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas.
Cholangiocarcinoma
Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms.
Cholangiocarcinoma
Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma.
Cholangiocarcinoma
FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma.
Cholangiocarcinoma
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
Cholangiocarcinoma
IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?
Cholangiocarcinoma
IDH1 mutation correlates with a beneficial prognosis and suppresses tumor growth in IHCC.
Cholangiocarcinoma
Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm.
Cholangiocarcinoma
Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.
Cholangiocarcinoma
Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.
Cholangiocarcinoma
Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?
Cholangiocarcinoma
Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2.
Cholangiocarcinoma
Mutant IDH1 confers resistance to energy stress in normal biliary cells through PFKP-induced aerobic glycolysis and AMPK activation.
Cholangiocarcinoma
Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma.
Cholangiocarcinoma
Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.
Cholangiocarcinoma
Potential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancers.
Cholangiocarcinoma
Predicting IDH mutation status of intrahepatic cholangiocarcinomas based on contrast-enhanced CT features.
Cholangiocarcinoma
Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.
Cholangiocarcinoma
Quantification of 2-Hydroxyglutarate Enantiomers by Liquid Chromatography-mass Spectrometry.
Cholangiocarcinoma
Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow.
Cholangiocarcinoma
Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
Cholangiocarcinoma
Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
Cholangiocarcinoma
Value of contrast-enhanced CT texture analysis in predicting IDH mutation status of intrahepatic cholangiocarcinoma.
Cholecystitis
HIGH SERUM TRANSAMINASE AND ISOCITRIC DEHYDROGENASE LEVELS IN A PATIENT WITH CHOLECYSTITIS AND SUBACUTE HEPATITIS.
Cholestasis
Relationship between antioxidant systems, intracellular thiols and DNA ploidy in liver of rats during experimental cirrhogenesis.
Chondroma
Beyond the Influence of IDH Mutations: Exploring Epigenetic Vulnerabilities in Chondrosarcoma.
Chondroma
IDH1 immunohistochemistry reactivity and mosaic IDH1 or IDH2 somatic mutations in pediatric sporadic enchondroma and enchondromatosis.
Chondroma
IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas.
Chondroma
Recurrent 12q13-15 chromosomal aberrations, high frequency of isocitrate dehydrogenase 1 mutations, and absence of high mobility group AT-hook 2 expression in periosteal chondromas.
Chondroma
Somatic mosaic mutations of IDH1 and NPM1 associated with cup-like acute myeloid leukemia in a patient with Maffucci syndrome.
Chondroma
The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.
Chondrosarcoma
An update of molecular pathology of bone tumors. Lessons learned from investigating samples by next generation sequencing.
Chondrosarcoma
Beyond the Influence of IDH Mutations: Exploring Epigenetic Vulnerabilities in Chondrosarcoma.
Chondrosarcoma
Cancer-associated isocitrate dehydrogenase mutations induce mitochondrial DNA instability.
Chondrosarcoma
Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma.
Chondrosarcoma
Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms.
Chondrosarcoma
IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas.
Chondrosarcoma
Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm.
Chondrosarcoma
Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status.
Chondrosarcoma
Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.
Chondrosarcoma
Isocitrate dehydrogenase mutations in chondrosarcoma: the crossroads between cellular metabolism and oncogenesis.
Chondrosarcoma
Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2.
Chondrosarcoma
Mutant IDH1 Depletion Downregulates Integrins and Impairs Chondrosarcoma Growth.
Chondrosarcoma
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.
Chondrosarcoma
Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.
Chondrosarcoma
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma.
Chondrosarcoma
Potential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancers.
Chondrosarcoma
Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma.
Chondrosarcoma
Squamous cell carcinoma arising in dedifferentiated chondrosarcoma proved by isocitrate dehydrogenase mutation analysis.
Chondrosarcoma
The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.
Chondrosarcoma
Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
Colonic Neoplasms
Recent Advances in Targeted Therapies for Advanced Gastrointestinal Malignancies.
Colorectal Neoplasms
Wild-type IDH2 protects nuclear DNA from oxidative damage and is a potential therapeutic target in colorectal cancer.
Colorectal Neoplasms, Hereditary Nonpolyposis
Nivolumab with radiation therapy in a glioblastoma patient with Lynch syndrome.
Coma
Effect of total hepatectomy on selected cerebral substrates and enzymes of the glycolytic pathways and Krebs cycle.
Coma
[Changes of some energy exchange parameters in the rat heart under insulin hypoglycemia]
Coma
[Energy metabolic changes and nerve cell damage in rats exposed to multiple administration of large-dose insulin].
Cysts
MR image phenotypes may add prognostic value to clinical features in IDH wild-type lower-grade gliomas.
Cysts
Sarcocystis fusiformis: some Krebs cycle enzymes in various fractions of sarcocysts of buffalo (Bubalus bubalis).
Dehydration
Crystal structure of the monomeric isocitrate dehydrogenase in the presence of NADP+: insight into the cofactor recognition, catalysis, and evolution.
Diabetic Nephropathies
Effect of yam (Dioscorea cayenensis) and dasheen (Colocassia esculenta) extracts on the kidney of streptozotocin-induced diabetic rats.
Digestive System Diseases
[Determination of serum isocitrate dehydrogenase in patients with hepatobiliary diseases]
Digestive System Diseases
[Diagnostic significance of serum isocitrate dehydrogenase in hepatobiliary diseases]
Dystonia
[Activity of oxidative enzymes during dosed exercise in healthy persons and in persons with neurocirculatory dystonia]
Enchondromatosis
Somatic mosaic mutations of IDH1 and NPM1 associated with cup-like acute myeloid leukemia in a patient with Maffucci syndrome.
Endometrial Neoplasms
Biochemical changes in endometrial carcinoma and their correlation to clinical outcome and prognosis.
Endometrial Neoplasms
The effects of PGC-1? on the proliferation and energy metabolism of malignant endometrial cancer cells.
Ependymoma
The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision.
Epilepsy
Association between IDH mutational status and tumor-associated epilepsy or venous thromboembolism in patients with grade II and III astrocytoma.
Epilepsy
Interstitial deletion of the long arm of chromosome 2 with normal levels of isocitrate dehydrogenase.
Esophageal Squamous Cell Carcinoma
Isocitrate dehydrogenase 2 contributes to radiation resistance of oesophageal squamous cell carcinoma via regulating mitochondrial function and ROS/pAKT signalling.
Esophageal Squamous Cell Carcinoma
Isocitrate dehydrogenase gene mutations and 2-hydroxyglutarate accumulation in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Prognostic and diagnostic potential of isocitrate dehydrogenase 1 in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
The clinical significance of isocitrate dehydrogenase 2 in esophageal squamous cell carcinoma.
Gallbladder Neoplasms
IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?
Gastritis
Isocitrate Dehydrogenase of Helicobacter pylori Potentially Induces Humoral Immune Response in Subjects with Peptic Ulcer Disease and Gastritis.
Giant Cell Tumor of Bone
Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone.
Giant Cell Tumors
A novel monoclonal antibody SMab-2 recognizes endogenous IDH2-R172S of chondrosarcoma.
Giant Cell Tumors
Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone.
Giant Cell Tumors
Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
Gingivitis
Expression of TET2 enzyme indicates enhanced epigenetic modification of cells in periodontitis.
Glioblastoma
A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults.
Glioblastoma
A new functional IDH2 genetic variant is associated with the risk of lung cancer.
Glioblastoma
Acquired somatic mutations of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) in preleukemic disorders.
Glioblastoma
Advances in genetic and epigenetic analyses of gliomas: a neuropathological perspective.
Glioblastoma
Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide.
Glioblastoma
An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival.
Glioblastoma
Analysis of the effect of photodynamic therapy with Fotoenticine on gliosarcoma cells.
Glioblastoma
Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma.
Glioblastoma
Association of Isocitrate Dehydrogenase (IDH) Status With Edema to Tumor Ratio and Its Correlation With Immune Infiltration in Glioblastoma.
Glioblastoma
Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma.
Glioblastoma
Association of plasma cell-free DNA with survival in patients with IDH wild-type glioblastoma.
Glioblastoma
BCAT1 is a New MR Imaging-related Biomarker for Prognosis Prediction in IDH1-wildtype Glioblastoma Patients.
Glioblastoma
Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine.
Glioblastoma
Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation.
Glioblastoma
Characterization of transcriptome profile and clinical features of a novel immunotherapy target CD204 in diffuse glioma.
Glioblastoma
Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial.
Glioblastoma
Clinical implications of hypoxia-inducible factor-1? and caveolin-1 overexpression in isocitrate dehydrogenase-wild type glioblastoma multiforme.
Glioblastoma
Clinical significance of the 2016 WHO classification in Japanese patients with gliomas.
Glioblastoma
Co-expression of cancer driver genes: IDH-wildtype glioblastoma-derived tumorspheres.
Glioblastoma
Comparison of L-Methyl-11C-Methionine PET With Magnetic Resonance Spectroscopy in Detecting Newly Diagnosed Glioma.
Glioblastoma
Comprehensive Analysis of PD-1 Gene Expression, Immune Characteristics and Prognostic Significance in 1396 Glioma Patients.
Glioblastoma
Computer-aided diagnosis of isocitrate dehydrogenase genotypes in glioblastomas from radiomic patterns.
Glioblastoma
Concordance analysis and diagnostic test accuracy review of IDH1 immunohistochemistry in glioblastoma.
Glioblastoma
Correlation Between Tumor Location and Clinical Properties of Glioblastomas in Frontal and Temporal Lobes.
Glioblastoma
Correlation of commercially available quantitative MGMT (O-6-methylguanine-DNA methyltransferase) promoter methylation scores and GBM patient survival.
Glioblastoma
Corrigendum: Distinguishing Pseudoprogression From True Early Progression in Isocitrate Dehydrogenase Wild-Type Glioblastoma by Interrogating Clinical, Radiological and Molecular Features.
Glioblastoma
Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations.
Glioblastoma
Dabrafenib Treatment in a Patient with an Epithelioid Glioblastoma and BRAF V600E Mutation.
Glioblastoma
Detection of Isocitrate Dehydrogenase Mutated Glioblastomas Through Anomaly Detection Analytics.
Glioblastoma
Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma.
Glioblastoma
Differential Predictors and Clinical Implications Associated With Long-Term Survivors in IDH Wildtype and Mutant Glioblastoma.
Glioblastoma
Differentiating between glioblastomas with and without isocitrate dehydrogenase gene mutation by findings on conventional magnetic resonance images.
Glioblastoma
Diffuse glioma - Rare homozygous IDH point mutation, is it an oncogenetic mechanism?
Glioblastoma
Distinguishing Pseudoprogression From True Early Progression in Isocitrate Dehydrogenase Wild-Type Glioblastoma by Interrogating Clinical, Radiological, and Molecular Features.
Glioblastoma
Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma.
Glioblastoma
Elevated Na/H exchanger 1 (SLC9A1) emerges as a marker for tumorigenesis and prognosis in gliomas.
Glioblastoma
Elevated TERT Expression in TERT-Wildtype Adult Diffuse Gliomas: Histological Evaluation with a Novel TERT-Specific Antibody.
Glioblastoma
Elucidation of the TMab-6 Monoclonal Antibody Epitope Against Telomerase Reverse Transcriptase.
Glioblastoma
Evolutionary Trajectories of IDHWT Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis.
Glioblastoma
EZH2-, CHD4-, and IDH-linked epigenetic perturbation and its association with survival in glioma patients.
Glioblastoma
False-Positive Measurement at 2-Hydroxyglutarate MR Spectroscopy in Isocitrate Dehydrogenase Wild-Type Glioblastoma: A Multifactorial Analysis.
Glioblastoma
Fluid attenuation in non-contrast-enhancing tumor (nCET): an MRI Marker for Isocitrate Dehydrogenase (IDH) mutation in Glioblastoma.
Glioblastoma
Frequent false-negative immunohistochemical staining with IDH1 (R132H)-specific H09 antibody on frozen section control slides: a potential pitfall in glioma diagnosis.
Glioblastoma
Gene Expression Profiling Stratifies IDH-Wildtype Glioblastoma With Distinct Prognoses.
Glioblastoma
Generative adversarial network for glioblastoma ensures morphologic variations and improves diagnostic model for isocitrate dehydrogenase mutant type.
Glioblastoma
Genome-wide methylation profiling identifies an essential role of reactive oxygen species in pediatric glioblastoma multiforme and validates a methylome specific for H3 histone family 3A with absence of G-CIMP/isocitrate dehydrogenase 1 mutation.
Glioblastoma
Genomic Prognosticators and Extent of Resection in Molecularly Subtyped World Health Organization Grade II and III Gliomas-A Single-Institution, Nine-Year Data.
Glioblastoma
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.
Glioblastoma
Glioblastoma Therapy Can Be Augmented by Targeting IDH1-Mediated NADPH Biosynthesis.
Glioblastoma
Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome.
Glioblastoma
Glutamate as chemotactic fuel for diffuse glioma cells: are they glutamate suckers?
Glioblastoma
High mobility group A1 expression shows negative correlation with recurrence time in patients with glioblastoma multiforme.
Glioblastoma
High-Resolution Cartography of the Transcriptome and Methylome Landscapes of Diffuse Gliomas.
Glioblastoma
Highly sensitive detection of TERT promoter mutations in recurrent glioblastomas using digital PCR.
Glioblastoma
Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer.
Glioblastoma
Identification of Hedgehog pathway responsive glioblastomas by isocitrate dehydrogenase mutation.
Glioblastoma
Identification of two core genes in glioblastomas with different isocitrate dehydrogenase mutation status.
Glioblastoma
IDH genotypes differentiation in glioblastomas using DWI and DSC-PWI in the enhancing and peri-enhancing region.
Glioblastoma
IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.
Glioblastoma
IDH mutations associated impact on related cancer epidemiology and subsequent effect toward HIF-1?.
Glioblastoma
IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.
Glioblastoma
Immunotherapy for secondary glioblastoma multiforme: toward an isocitrate dehydrogenase vaccine.
Glioblastoma
Impact of epidemiological characteristics of supratentorial gliomas in adults brought about by the 2016 world health organization classification of tumors of the central nervous system.
Glioblastoma
In vitro visualization and characterization of wild type and mutant IDH homo- and heterodimers using Bimolecular Fluorescence Complementation.
Glioblastoma
Increased 14C-acetate accumulation in IDH-mutated human glioblastoma: implications for detecting IDH-mutated glioblastoma with 11C-acetate PET imaging.
Glioblastoma
Increased HOXA5 expression provides a selective advantage for gain of whole chromosome 7 in IDH wild-type glioblastoma.
Glioblastoma
Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis.
Glioblastoma
Insular primary glioblastomas with IDH mutations: Clinical and biological specificities.
Glioblastoma
Integrated metabolomics and lipidomics analyses reveal metabolic reprogramming in human glioma with IDH1 mutation.
Glioblastoma
Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities.
Glioblastoma
Integrative transcriptome analysis identified a BMP signaling pathway-regulated lncRNA AC068643.1 in IDH mutant and wild-type glioblastomas.
Glioblastoma
Intratumor heterogeneity, microenvironment, and mechanisms of drug resistance in glioma recurrence and evolution.
Glioblastoma
Isocitrate dehydrogenase (IDH) status prediction in histopathology images of gliomas using deep learning.
Glioblastoma
Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas.
Glioblastoma
Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
Glioblastoma
Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.
Glioblastoma
Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Glioblastoma
Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas.
Glioblastoma
Isocitrate dehydrogenase mutations in defining the biology of and supporting clinical decision making in glioblastoma.
Glioblastoma
Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications.
Glioblastoma
Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma.
Glioblastoma
Isocitrate dehydrogenase1 mutation reduces the pericyte coverage of microvessels in astrocytic tumours.
Glioblastoma
Label-free highly sensitive detection of DNA approximate length and concentration by impedimetric CRISPR-dCas9 based biosensor technology.
Glioblastoma
Less Invasive Phenotype Found in Isocitrate Dehydrogenase-mutated Glioblastomas than in Isocitrate Dehydrogenase Wild-Type Glioblastomas: A Diffusion-Tensor Imaging Study.
Glioblastoma
Lithium chloride decreases proliferation and migration of C6 glioma cells harboring isocitrate dehydrogenase 2 mutant via GSK-3?
Glioblastoma
Long-Term Survival in Primary Glioblastoma With Versus Without Isocitrate Dehydrogenase Mutations.
Glioblastoma
Low co-expression of epidermal growth factor receptor and its chaperone heat shock protein 90 is associated with worse prognosis in primary glioblastoma, IDH-wild-type.
Glioblastoma
Magnetic Resonance Imaging Reveals a Pronounced Treatment Response of a Isocitrate Dehydrogenase- and B-Raf Proto-Oncogene-Wildtype Epithelioid Glioblastoma.
Glioblastoma
Mathematical analysis predicts imbalanced IDH1/2 expression associates with 2-HG-inactivating ?-oxygenation pathway in colorectal cancer.
Glioblastoma
MiR-16-5p is frequently down-regulated in astrocytic gliomas and modulates glioma cell proliferation, apoptosis and response to cytotoxic therapy.
Glioblastoma
Molecular and clinical characterization of CD163 expression via large-scale analysis in glioma.
Glioblastoma
Molecular classification of IDH-mutant glioblastomas based on gene expression profiles.
Glioblastoma
Molecular diagnostics of gliomas using next generation sequencing of a glioma-tailored gene panel.
Glioblastoma
Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation.
Glioblastoma
Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma.
Glioblastoma
MRI and 18FET-PET predict survival benefit from bevacizumab plus radiotherapy in patients with IDH wild-type glioblastoma: results from the randomized ARTE trial.
Glioblastoma
MRI Atlas of IDH Wild-Type Supratentorial Glioblastoma: Probabilistic Maps of Phenotype, Management, and Outcomes.
Glioblastoma
MRI Features May Predict Molecular Features of Glioblastoma in Isocitrate Dehydrogenase Wild-Type Lower-Grade Gliomas.
Glioblastoma
Multicentric Registry Study on Epidemiological and Biological Disease Profile as Well as Clinical Outcome in Patients with Low-Grade Gliomas: The LoG-Glio Project.
Glioblastoma
Mutant IDH1 cooperates with ATRX loss to drive the alternative lengthening of telomere (ALT) phenotype in glioma.
Glioblastoma
Mutant-allele tumor heterogeneity in malignant glioma effectively predicts neoplastic recurrence.
Glioblastoma
Mutations in isocitrate dehydrogenase 2 accelerate glioma cell migration via matrix metalloproteinase-2 and 9
Glioblastoma
Mutations in isocitrate dehydrogenase 2 accelerate glioma cell migration via matrix metalloproteinase-2 and 9.
Glioblastoma
Myoinositol to Total Choline Ratio in Glioblastomas as a Potential Prognostic Factor in Preoperative Magnetic Resonance Spectroscopy.
Glioblastoma
N2M2 (NOA20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma.
Glioblastoma
Near haploidization is a genomic hallmark which defines a molecular subgroup of giant cell glioblastoma.
Glioblastoma
Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.
Glioblastoma
Next Generation Sequencing-Based Transcriptome Predicts Bevacizumab Efficacy in Combination with Temozolomide in Glioblastoma.
Glioblastoma
Nivolumab with radiation therapy in a glioblastoma patient with Lynch syndrome.
Glioblastoma
Non-invasive detection of 2-hydroxyglutarate in IDH-mutated gliomas using two-dimensional localized correlation spectroscopy (2D L-COSY) at 7 Tesla.
Glioblastoma
Non-measurable speckled contrast-enhancing lesions appearing during course of disease are associated with IDH mutation in high-grade astrocytoma patients.
Glioblastoma
O(6)-methyl-guanine-DNA methyltransferase methylation and IDH1/2 mutation in small cell lung cancer.
Glioblastoma
O6-methylguanine-DNA methyltransferase promoter methylation and isocitrate dehydrogenase mutation as prognostic factors in a cohort of Saudi patients with glioblastoma.
Glioblastoma
Oncogenes and Clotting Factors: The Emerging Role of Tumor Cell Genome and Epigenome in Cancer-Associated Thrombosis.
Glioblastoma
Outcomes of salvage fractionated re-irradiation combined with bevacizumab for recurrent high-grade gliomas that progressed after bevacizumab treatment*.
Glioblastoma
Papillary glioblastoma exhibiting a neuroradiological cyst with a mural nodule: A case report.
Glioblastoma
Partial resection offers an overall survival benefit over biopsy in MGMT-unmethylated IDH-wildtype glioblastoma patients.
Glioblastoma
Pathologic diversity of glioneuronal tumor with neuropil-like islands: A histological and immunohistochemical study with a special reference to isocitrate dehydrogenase 1 (IDH1) in 5 cases.
Glioblastoma
Prediction of Core Signaling Pathway by Using Diffusion- and Perfusion-based MRI Radiomics and Next-generation Sequencing in Isocitrate Dehydrogenase Wild-type Glioblastoma.
Glioblastoma
Preoperative imaging of glioblastoma patients using hyperpolarized 13C pyruvate: Potential role in clinical decision making.
Glioblastoma
Preoperative inflammation markers and IDH mutation status predict glioblastoma patient survival.
Glioblastoma
Primary Focal Intracranial Leptomeningeal Glioma: Case Report and Review of the Literature.
Glioblastoma
Prognostic impact of CDKN2A/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma.
Glioblastoma
Prognostic significance of IDH 1 mutation in patients with glioblastoma multiforme.
Glioblastoma
Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back?
Glioblastoma
Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma.
Glioblastoma
Quantification of 2-Hydroxyglutarate Enantiomers by Liquid Chromatography-mass Spectrometry.
Glioblastoma
Radiogenomic modeling predicts survival-associated prognostic groups in glioblastoma.
Glioblastoma
Radiological and pathological features associated with IDH1-R132H mutation status and early mortality in newly diagnosed anaplastic astrocytic tumours.
Glioblastoma
Radiomic model for predicting mutations in the isocitrate dehydrogenase gene in glioblastomas.
Glioblastoma
Recent Developments and Future Directions in Adult Lower-Grade Gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) Consensus.
Glioblastoma
Relationship between tumor cell infiltration and 5-aminolevulinic acid fluorescence signals after resection of MR-enhancing lesions and its prognostic significance in glioblastoma.
Glioblastoma
Relaxation-compensated amide proton transfer (APT) MRI signal intensity is associated with survival and progression in high-grade glioma patients.
Glioblastoma
Remarkable response of a patient with secondary glioblastoma to a histone deacetylase inhibitor.
Glioblastoma
Reproducible imaging-based prediction of molecular subtype and risk stratification of gliomas across different experience levels using a structured reporting system.
Glioblastoma
Ribosomal Protein S27/Metallopanstimulin-1 (RPS27) in Glioma-A New Disease Biomarker?
Glioblastoma
Role of asparagine endopeptidase in mediating wild-type p53 inactivation of glioblastoma.
Glioblastoma
Secondary glioblastomas with IDH1/2 mutations have longer glioma history from preceding lower-grade gliomas.
Glioblastoma
Solitary primary intracranial leptomeningeal glioblastoma invading the normal cortex: Case report.
Glioblastoma
Somatostatin receptor 2A in gliomas: Association with oligodendrogliomas and favourable outcome.
Glioblastoma
Spatiotemporal Heterogeneity in Multiparametric Physiologic MRI Is Associated with Patient Outcomes in IDH-Wildtype Glioblastoma.
Glioblastoma
Steroids from Ganoderma sinense as new natural inhibitors of cancer-associated mutant IDH1.
Glioblastoma
Surgery of Insular Diffuse Gliomas-Part 1: Transcortical Awake Resection Is Safe and Independently Improves Overall Survival.
Glioblastoma
Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status.
Glioblastoma
T2 mapping of the peritumoral infiltration zone of glioblastoma and anaplastic astrocytoma.
Glioblastoma
Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.
Glioblastoma
Telomerase reverse transcriptase promoter mutation- and O6-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?
Glioblastoma
Temozolomide for patients with wild-type isocitrate dehydrogenase (IDH) 1 glioblastoma using propensity score matching.
Glioblastoma
Temozolomide radiochemotherapy for high-grade glioma patients with hemodialysis: a case series of 7 patients.
Glioblastoma
The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision.
Glioblastoma
The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas.
Glioblastoma
The emerging role of d-2-hydroxyglutarate as an oncometabolite in hematolymphoid and central nervous system neoplasms.
Glioblastoma
The glutamine antagonist prodrug JHU-083 slows malignant glioma growth and disrupts mTOR signaling.
Glioblastoma
The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade II Cerebral Gliomas in Adults: Version 2019.01.
Glioblastoma
The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade III Cerebral Gliomas in Adults: Version 2019.01.
Glioblastoma
The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma.
Glioblastoma
The role of 2-hydroxyglutarate magnetic resonance spectroscopy for the determination of isocitrate dehydrogenase status in lower grade gliomas versus glioblastoma: a systematic review and meta-analysis of diagnostic test accuracy.
Glioblastoma
The Role of Delayed Radiotherapy Initiation in Patients with Newly Diagnosed Glioblastoma with Residual Tumor Mass.
Glioblastoma
Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation.
Glioblastoma
Ultra-Mutation in IDH Wild-Type Glioblastomas of Patients Younger than 55 Years is Associated with Defective Mismatch Repair, Microsatellite Instability, and Giant Cell Enrichment.
Glioblastoma
Voxel-wise radiogenomic mapping of tumor location with key molecular alterations in patients with glioma.
Glioblastoma
Warburg tumours and the mechanisms of mitochondrial tumour suppressor genes. Barking up the right tree?
Glioblastoma
[Glioblastoma with BRAFV600E mutation and numerous metastatic foci: a case report].
Glioma
11C-Methionine Integrated PET/MRI-Based Texture Analysis Features May Have a Potential Ability to Distinguish Oligodendroglioma (IDH-Mutant and 1p/19q-Codeleted) From Varied Gliomas.
Glioma
18F-FDOPA PET for the non-invasive prediction of glioma molecular parameters: a radiomics study.
Glioma
1p/19q co-deletion status is associated with distinct tumor-associated macrophage infiltration in IDH mutated lower-grade gliomas.
Glioma
2-Hydroxyglutarate Detection by Short Echo Time Magnetic Resonance Spectroscopy in Routine Imaging Study of Brain Glioma at 3.0 T.
Glioma
2-hydroxyglutarate MR Spectroscopy for Prediction of Isocitrate Dehydrogenase Mutant Glioma: A Systemic Review and Meta-analysis using Individual Patient Data.
Glioma
2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
Glioma
A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics.
Glioma
A comparative study of short- and long-TE (1) H MRS at 3 T for in vivo detection of 2-hydroxyglutarate in brain tumors.
Glioma
A comprehensive review of available omics data resources and molecular profiling for precision glioma studies.
Glioma
A high-throughput analysis of the IDH1(R132H) protein expression in pituitary adenomas.
Glioma
A juvenile case of epilepsy-associated, isocitrate dehydrogenase wild-type/histone 3 wild-type diffuse glioma with a rare BRAF A598T mutation.
Glioma
A Non-invasive Radiomic Method Using 18F-FDG PET Predicts Isocitrate Dehydrogenase Genotype and Prognosis in Patients With Glioma.
Glioma
A Noninvasive Comparison Study between Human Gliomas with IDH1 and IDH2 Mutations by MR Spectroscopy.
Glioma
A novel fully automated MRI-based deep-learning method for classification of 1p/19q co-deletion status in brain gliomas.
Glioma
A novel fully automated MRI-based deep-learning method for classification of IDH mutation status in brain gliomas.
Glioma
A novel monoclonal antibody SMab-2 recognizes endogenous IDH2-R172S of chondrosarcoma.
Glioma
A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model.
Glioma
A surgical strategy for lower grade gliomas using intraoperative molecular diagnosis.
Glioma
Absence of R140Q mutation of isocitrate dehydrogenase 2 in gliomas and breast cancers.
Glioma
Absolute quantification of 2-hydroxyglutarate on tissue by matrix-assisted laser desorption/ionization mass spectrometry imaging for rapid and precise identification of isocitrate dehydrogenase mutations in human glioma.
Glioma
Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy.
Glioma
Accuracy of 2-hydroxyglutarate quantification by short-echo proton-MRS at 3 T: A phantom study.
Glioma
Advances in genetic and epigenetic analyses of gliomas: a neuropathological perspective.
Glioma
Alpha Internexin: A Surrogate Marker for 1p/19q Codeletion and Prognostic Marker in Anaplastic (WHO grade III) Gliomas.
Glioma
Anaplastic oligodendroglioma metastasizing to the bone marrow: a unique case report and literature review.
Glioma
Apparent diffusion coefficient for molecular subtyping of non-gadolinium-enhancing WHO grade II/III glioma: volumetric segmentation versus two-dimensional region of interest analysis.
Glioma
Application of denaturing capillary electrophoresis for the detection of prognostic mutations in isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 genes in brain tumors.
Glioma
Application of Distributed Parameter Model to Assessment of Glioma IDH Mutation Status by Dynamic Contrast-Enhanced Magnetic Resonance Imaging.
Glioma
Association between Tumor Acidity and Hypervascularity in Human Gliomas Using pH-Weighted Amine Chemical Exchange Saturation Transfer Echo-Planar Imaging and Dynamic Susceptibility Contrast Perfusion MRI at 3T.
Glioma
Association of Circadian Clock Gene Expression with Glioma Tumor Microenvironment and Patient Survival.
Glioma
Association of dynamic susceptibility magnetic resonance imaging at initial tumor diagnosis with the prognosis of different molecular glioma subtypes.
Glioma
Association of IDH mutation and 1p19q co-deletion with tumor immune microenvironment in lower-grade glioma.
Glioma
Association of preoperative seizures with tumor metabolites quantified by magnetic resonance spectroscopy in gliomas.
Glioma
Association of XRCC3 rs1799794 polymorphism with survival of glioblastoma multiforme patients treated with combined radio-chemotherapy.
Glioma
ATM mutations improve radio-sensitivity in wild-type isocitrate dehydrogenase-associated high-grade glioma: retrospective analysis using next-generation sequencing data.
Glioma
Autocrine BMP4 Signaling Enhances Tumor Aggressiveness via Promoting Wnt/?-Catenin Signaling in IDH1-mutant Gliomas.
Glioma
Automated apparent diffusion coefficient analysis for genotype prediction in lower grade glioma: association with the T2-FLAIR mismatch sign.
Glioma
Automated machine learning to predict the co-occurrence of isocitrate dehydrogenase mutations and O6 -methylguanine-DNA methyltransferase promoter methylation in patients with gliomas.
Glioma
B2M overexpression correlates with malignancy and immune signatures in human gliomas.
Glioma
Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective?
Glioma
Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation.
Glioma
Cancer-associated isocitrate dehydrogenase mutations induce mitochondrial DNA instability.
Glioma
CARD-Associated Risk Score Features the Immune Landscape and Predicts the Responsiveness to Anti-PD-1 Therapy in IDH Wild-Type Gliomas.
Glioma
Case Report of Complete Radiological Response of a Thalamic Glioblastoma After Treatment With Proton Therapy Followed by Temozolomide and Tumor-Treating Fields.
Glioma
Case Report: Clinical Outcome and Image Response of Two Patients With Secondary High-Grade Glioma Treated With Chemoradiation, PCV, and Cannabidiol.
Glioma
CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Glioma
Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma.
Glioma
Cerebellar high-grade astrocytoma with IDH mutations in the elderly: A report of two cases.
Glioma
Characterisation of isocitrate dehydrogenase gene mutant WHO grade 2 and 3 gliomas: MRI predictors of 1p/19q co-deletion and tumour grade.
Glioma
Characteristics of the isocitrate dehydrogenase gene and telomerase reverse transcriptase promoter mutations in gliomas in Chinese patients.
Glioma
Characterization of systemic immunosuppression by IDH mutant glioma small extracellular vesicles.
Glioma
Characterization of transcriptome profile and clinical features of a novel immunotherapy target CD204 in diffuse glioma.
Glioma
Chromatin insulation dynamics in glioblastoma: challenges and future perspectives of precision oncology.
Glioma
CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Glioma
Classification of brain tumor isocitrate dehydrogenase status using MRI and deep learning.
Glioma
Clinical prognostic value of isocitrate dehydrogenase mutation, O-6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in glioma patients.
Glioma
Clinical significance of the 2016 WHO classification in Japanese patients with gliomas.
Glioma
Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas.
Glioma
Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors.
Glioma
Commentary: The Correlation of Fluorescence of Protoporphyrinogen IX and Status of Isocitrate Dehydrogenase in Gliomas.
Glioma
Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms.
Glioma
Comparative Value of 2-Hydroxyglutarate-to-Lipid and Lactate Ratio versus 2-Hydroxyglutarate Concentration on MR Spectroscopic Images for Predicting Isocitrate Dehydrogenase Mutation Status in Gliomas.
Glioma
Comparison of Genetic Profiles and Prognosis of High-Grade Gliomas Using Quantitative and Qualitative MRI Features: A Focus on G3 Gliomas.
Glioma
Comparison of L-Methyl-11C-Methionine PET With Magnetic Resonance Spectroscopy in Detecting Newly Diagnosed Glioma.
Glioma
Comparison of Radiomics Analyses Based on Different Magnetic Resonance Imaging Sequences in Grading and Molecular Genomic Typing of Glioma.
Glioma
Comparison of [18F]Fluoroethyltyrosine PET and Sodium MRI in Cerebral Gliomas: a Pilot Study.
Glioma
Computational Analysis of IDH1, IDH2, and TP53 Mutations in Low-Grade Gliomas Including Oligodendrogliomas and Astrocytomas.
Glioma
Conditions for (13)C NMR detection of 2-hydroxyglutarate in tissue extracts from isocitrate dehydrogenase-mutated gliomas.
Glioma
Contrast enhancement is a prognostic factor in IDH1/2 mutant, but not in wild-type WHO grade II/III glioma as confirmed by machine learning.
Glioma
Conventional MR-based Preoperative Nomograms for Prediction of IDH/1p19q Subtype in Low-Grade Glioma.
Glioma
Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.
Glioma
Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase.
Glioma
Current and future tools for determination and monitoring of isocitrate dehydrogenase status in gliomas.
Glioma
D-2-Hydroxyglutarate does not mimic all the IDH mutation effects, in particular the reduced etoposide-triggered apoptosis mediated by an alteration in mitochondrial NADH.
Glioma
D-2-Hydroxyglutarate Is an Intercellular Mediator in IDH-Mutant Gliomas Inhibiting Complement and T Cells.
Glioma
Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq.
Glioma
Deep cross-view co-regularized representation learning for glioma subtype identification.
Glioma
Detection of "oncometabolite" 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma.
Glioma
Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation.
Glioma
Detection of IDH1 and IDH2 Mutation in Formalin-fixed Paraffin-embedded Gliomas Using Allele-specific COLD-PCR and Probe Melting Curve Analysis.
Glioma
Detection of IDH1 and TERT promoter mutations with droplet digital PCR in diffuse gliomas.
Glioma
Determining IDH-Mutational Status in Gliomas Using IDH1-R132H Antibody and Polymerase Chain Reaction.
Glioma
Development of a Microfluidic Culture Paradigm for Ex Vivo Maintenance of Human Glioblastoma Tissue: A New Glioblastoma Model?
Glioma
Diagnostic accuracy and potential covariates for machine learning to identify IDH mutations in glioma patients: evidence from a meta-analysis.
Glioma
Diagnostic Accuracy of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy in Newly-Diagnosed Brain Mass and Suspected Recurrent Gliomas.
Glioma
Diagnostic advantage of double immunohistochemistry using two mutation-specific anti-IDH antibodies (HMab-1 and MsMab-1) in gliomas.
Glioma
Diagnostic value of PET/CT with 11C-methionine (MET) and 18F-fluorothymidine (FLT) in newly diagnosed glioma based on the 2016 WHO classification.
Glioma
Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET.
Glioma
Diffuse glioma - Rare homozygous IDH point mutation, is it an oncogenetic mechanism?
Glioma
Diffuse gliomas in patients aged 55?years or over: A suggestion for IDH mutation testing.
Glioma
Diffusion tensor imaging radiomics in lower-grade glioma: improving subtyping of isocitrate dehydrogenase mutation status.
Glioma
Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
Glioma
Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation.
Glioma
DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.
Glioma
DNA Methylation Analysis Identifies Patterns in Progressive Glioma Grades to Predict Patient Survival.
Glioma
DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development.
Glioma
Dynamic 18F-Fluoro-Ethyl-Tyrosine Positron Emission Tomography/ Computed Tomography: A Better Predictor of Isocitrate Dehydrogenase Mutation in Presurgical Evaluations of Glioma.
Glioma
Echo-planar spectroscopic imaging with dual-readout alternated gradients (DRAG-EPSI) at 7 T: Application for 2-hydroxyglutarate imaging in glioma patients.
Glioma
Editorial for "Predicting Isocitrate Dehydrogenase (IDH) Mutation Status in Gliomas Using Multiparameter MRI Radiomics Features".
Glioma
Elevated expression of fatty acid synthase and nuclear localization of carnitine palmitoyltransferase 1C are common among human gliomas.
Glioma
Elevated Na/H exchanger 1 (SLC9A1) emerges as a marker for tumorigenesis and prognosis in gliomas.
Glioma
Emerging interplay of genetics and epigenetics in gliomas: a new hope for targeted therapy.
Glioma
Epitope mapping of an anti-alpha thalassemia/mental retardation syndrome X-linked monoclonal antibody AMab-6.
Glioma
Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.
Glioma
Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations.
Glioma
Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience.
Glioma
Evaluation of IDH1 status in diffusely infiltrating gliomas by immunohistochemistry using anti-mutant and wild type IDH1 antibodies.
Glioma
Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1/2 gene mutation using histogram analysis of diffusion-weighted imaging and dynamic-susceptibility contrast perfusion imaging.
Glioma
Exploring the regulatory role of isocitrate dehydrogenase mutant protein on glioma stem cell proliferation.
Glioma
Expression of Hedgehog ligand and signal transduction components in mutually distinct isocitrate dehydrogenase mutant glioma cells supports a role for paracrine signaling.
Glioma
Expression of m6A Regulators Correlated With Immune Microenvironment Predicts Therapeutic Efficacy and Prognosis in Gliomas.
Glioma
Expression Profile Analysis of Zinc Transporters (ZIP4, ZIP9, ZIP11, ZnT9) in Gliomas and their Correlation with IDH1 Mutation Status.
Glioma
Expression profiling of the adhesion G protein-coupled receptor GPR133 (ADGRD1) in glioma subtypes.
Glioma
Extent of Surgical Resection in Lower-Grade Gliomas: Differential Impact Based on Molecular Subtype.
Glioma
EZH2-, CHD4-, and IDH-linked epigenetic perturbation and its association with survival in glioma patients.
Glioma
False-Positive Measurement at 2-Hydroxyglutarate MR Spectroscopy in Isocitrate Dehydrogenase Wild-Type Glioblastoma: A Multifactorial Analysis.
Glioma
FGFR3 overexpression is a useful detection tool for FGFR3 fusions and sequence variations in glioma.
Glioma
Fitting algorithms and baseline correction influence the results of non-invasive in vivo quantitation of 2-hydroxyglutarate with 1 H-MRS.
Glioma
Frequent Diagnostic Under-Grading in Isocitrate Dehydrogenase Wild-Type Gliomas due to Small Pathological Tissue Samples.
Glioma
Frequent false-negative immunohistochemical staining with IDH1 (R132H)-specific H09 antibody on frozen section control slides: a potential pitfall in glioma diagnosis.
Glioma
Frequent IDH1/2 mutations in intracranial chondrosarcoma: a possible diagnostic clue for its differentiation from chordoma.
Glioma
Fully Automated Hybrid Approach to Predict the IDH Mutation Status of Gliomas via Deep Learning and Radiomics.
Glioma
Functional alteration of canine isocitrate dehydrogenase 2 (IDH2) via an R174K mutation.
Glioma
Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma.
Glioma
Genomic Prognosticators and Extent of Resection in Molecularly Subtyped World Health Organization Grade II and III Gliomas-A Single-Institution, Nine-Year Data.
Glioma
Glioblastoma multiforme: Metabolic differences to peritumoral tissue and IDH-mutated gliomas revealed by mass spectrometry imaging.
Glioma
Glioma Grading and Determination of IDH Mutation Status and ATRX loss by DCE and ASL Perfusion.
Glioma
Glioma-derived mutations in isocitrate dehydrogenase 2 beneficial to traditional chemotherapy.
Glioma
GNG5 is a novel oncogene associated with cell migration, proliferation, and poor prognosis in glioma.
Glioma
Heterogeneous parameters based on 18F-FET PET imaging can non-invasively predict tumor grade and isocitrate dehydrogenase gene 1 mutation in untreated gliomas.
Glioma
HHLA2 is a novel prognostic predictor and potential therapeutic target in malignant glioma.
Glioma
High-grade gliomas with isocitrate dehydrogenase wild-type and 1p/19q codeleted: Atypical molecular phenotype and current challenges in molecular diagnosis.
Glioma
High-Resolution Cartography of the Transcriptome and Methylome Landscapes of Diffuse Gliomas.
Glioma
Highly specific determination of IDH status using edited in vivo magnetic resonance spectroscopy.
Glioma
Histopathological grading affects survival in patients with IDH-mutant grade II and grade III diffuse gliomas.
Glioma
Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation status.
Glioma
Hub gene identification and prognostic model construction for isocitrate dehydrogenase mutation in glioma.
Glioma
Hybrid 11C-MET PET/MRI Combined With "Machine Learning" in Glioma Diagnosis According to the Revised Glioma WHO Classification 2016.
Glioma
Hypermethylation of LATS2 Promoter and Its Prognostic Value in IDH-Mutated Low-Grade Gliomas.
Glioma
Hypoxia and glucose metabolism assessed by FMISO and FDG PET for predicting IDH1 mutation and 1p/19q codeletion status in newly diagnosed malignant gliomas.
Glioma
Hypoxia-associated factor expression in low-grade and anaplastic gliomas: a marker of poor outcome.
Glioma
Identification of a Good-Prognosis IDH-Mutant-Like Population of Patients with Diffuse Gliomas.
Glioma
Identification of a three-long non-coding RNA signature for predicting survival of temozolomide-treated isocitrate dehydrogenase mutant low-grade gliomas.
Glioma
Identification of Hedgehog pathway responsive glioblastomas by isocitrate dehydrogenase mutation.
Glioma
Identification of IDH and TERTp mutation status using 1 H-MRS in 112 hemispheric diffuse gliomas.
Glioma
Identification of integrative molecular and clinical profiles of Fibrinogen-like protein 2 in gliomas using 1323 samples.
Glioma
Identification of New Biomarkers Associated With IDH Mutation and Prognosis in Astrocytic Tumors Using NanoString nCounter Analysis System.
Glioma
Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma.
Glioma
IDH mutation and 1p19q codeletion distinguish two radiological patterns of diffuse low-grade gliomas.
Glioma
IDH Mutation Detection in Formalin-Fixed Paraffin-Embedded Gliomas Using Multiplex PCR and Single-base Extension.
Glioma
IDH mutations associated impact on related cancer epidemiology and subsequent effect toward HIF-1?.
Glioma
IDH-Mutant Brain Tumors Hit the Achilles' Heel of Macrophages with R-2-Hydroxyglutarate.
Glioma
IDH-mutant brainstem gliomas in adolescent and young adult patients: Report of three cases and review of the literature.
Glioma
IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification.
Glioma
IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.
Glioma
IDH1 mutations in gliomas: First series from a tertiary care centre in India with comprehensive review of literature.
Glioma
IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy.
Glioma
IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.
Glioma
IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis.
Glioma
IDH2 compensates for IDH1 mutation to maintain cell survival under hypoxic conditions in IDH1?mutant tumor cells.
Glioma
IDH2 Deficiency in Microglia Decreases the Pro-inflammatory Response via the ERK and NF-?B Pathways.
Glioma
IDH2 reprograms mitochondrial dynamics in cancer through a HIF-1?-regulated pseudohypoxic state.
Glioma
Imaging prediction of isocitrate dehydrogenase (IDH) mutation in patients with glioma: a systemic review and meta-analysis.
Glioma
Immune checkpoint molecule herpes virus entry mediator is overexpressed and associated with poor prognosis in human glioblastoma.
Glioma
Immune-related genes with APA in microenvironment indicate risk stratification and clinical prognosis in grade II/III gliomas.
Glioma
Immunohistochemical expression of IDH1 in gliomas: a tissue microarray-based approach.
Glioma
Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas.
Glioma
Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
Glioma
In vitro visualization and characterization of wild type and mutant IDH homo- and heterodimers using Bimolecular Fluorescence Complementation.
Glioma
In vivo 2-hydroxyglutarate-proton magnetic resonance spectroscopy (3 T, PRESS technique) in treatment-naïve suspect lower-grade gliomas: feasibility and accuracy in a clinical setting.
Glioma
In vivo MRS measurement of 2-hydroxyglutarate in patient-derived IDH-mutant xenograft mouse models versus glioma patients.
Glioma
In-Vivo Proton Magnetic Resonance Spectroscopy of 2-Hydroxyglutarate in Isocitrate Dehydrogenase-Mutated Gliomas: A Technical Review for Neuroradiologists.
Glioma
Incidence of biomarkers in high-grade gliomas and their impact on survival in a diverse SouthEast Asian cohort - a population-based study.
Glioma
Increased intratumoral infiltration in IDH wild-type lower-grade gliomas observed with diffusion tensor imaging.
Glioma
Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm.
Glioma
Increased RLIP76 expression in IDH1 wild?type glioblastoma multiforme is associated with worse prognosis.
Glioma
Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis.
Glioma
Integrated metabolomics and lipidomics analyses reveal metabolic reprogramming in human glioma with IDH1 mutation.
Glioma
Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma.
Glioma
Interaction between IDH1 WT and calmodulin and its implications for glioblastoma cell growth and migration.
Glioma
Intraoperative assessment of isocitrate dehydrogenase mutation status in human gliomas using desorption electrospray ionization-mass spectrometry.
Glioma
Intraoperative detection of isocitrate dehydrogenase mutations in human gliomas using a miniature mass spectrometer.
Glioma
Intratumor heterogeneity, microenvironment, and mechanisms of drug resistance in glioma recurrence and evolution.
Glioma
Isocitrate dehydrogenase (IDH) status prediction in histopathology images of gliomas using deep learning.
Glioma
Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas.
Glioma
Isocitrate dehydrogenase 1 mutation is associated with reduced levels of inflammation in glioma patients.
Glioma
Isocitrate dehydrogenase 1-mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress.
Glioma
Isocitrate dehydrogenase 1R132H mutation in microglia/macrophages in gliomas: Indication of a significant role of microglia/macrophages in glial tumorigenesis.
Glioma
Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1.
Glioma
Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms.
Glioma
Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone.
Glioma
Isocitrate Dehydrogenase Mutation Leads to Alteration in 3-Dimensional DNA Structure and Oncogene Activation in Gliomas.
Glioma
Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Glioma
Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications.
Glioma
Isocitrate Dehydrogenase Mutations in Glioma: From Basic Discovery to Therapeutics Development.
Glioma
Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications.
Glioma
Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target.
Glioma
Isocitrate Dehydrogenase Mutations in Low-Grade Gliomas Correlate With Prolonged Overall Survival in Older Patients.
Glioma
Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients.
Glioma
Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.
Glioma
Isocitrate dehydrogenase mutations: A challenge to traditional views on the genesis and malignant progression of gliomas.
Glioma
Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma.
Glioma
Isocitrate Dehydrogenase, Patient-Reported Outcomes, and Cognitive Functioning of Glioma Patients: a Systematic Review.
Glioma
Kiaa0101 serves as a prognostic marker and promotes invasion by regulating p38/snail1 pathway in glioma.
Glioma
Large-Scale Drug Screening in Patient-Derived IDHmut Glioma Stem Cells Identifies Several Efficient Drugs among FDA-Approved Antineoplastic Agents.
Glioma
Linking epigenetic signature and metabolic phenotype in IDH mutant and IDH wildtype diffuse glioma.
Glioma
Lithium chloride decreases proliferation and migration of C6 glioma cells harboring isocitrate dehydrogenase 2 mutant via GSK-3?
Glioma
Long Non-coding RNA Expression Profiling Identifies a Four-Long Non-coding RNA Prognostic Signature for Isocitrate Dehydrogenase Mutant Glioma.
Glioma
Long-Term Survival in Primary Glioblastoma With Versus Without Isocitrate Dehydrogenase Mutations.
Glioma
Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas.
Glioma
Lower apparent diffusion coefficients indicate distinct prognosis in low-grade and high-grade glioma.
Glioma
Machine learning and radiomic phenotyping of lower grade gliomas: improving survival prediction.
Glioma
Machine learning assisted DSC-MRI radiomics as a tool for glioma classification by grade and mutation status.
Glioma
Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas.
Glioma
Magnetic Resonance Imaging Derived Biomarkers of IDH Mutation Status and Overall Survival in Grade III Astrocytomas.
Glioma
Magnetic Resonance Spectrobiopsy for Prediction of Isocitrate Dehydrogenase Mutation in Glioma.
Glioma
Magnetic Resonance Spectroscopic Assessment of IDH Status in gliomas: The New Frontiers of Spectrobiopsy in Neurodiagnostics.
Glioma
Magnetic Resonance Spectroscopy for Detection of 2-Hydroxyglutarate as a Biomarker for IDH Mutation in Gliomas.
Glioma
Magnetic Resonance Spectroscopy for Identification of Isocitrate Dehydrogenase Mutation in Gliomas.
Glioma
Magnetic resonance spectroscopy of isocitrate dehydrogenase mutated gliomas: current knowledge on the neurochemical profile.
Glioma
Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2.
Glioma
Methylation dependent down-regulation of G0S2 leads to suppression of invasion and improved prognosis of IDH1-mutant glioma.
Glioma
MicroRNA-183 upregulates HIF-1? by targeting isocitrate dehydrogenase 2 (IDH2) in glioma cells.
Glioma
MiR-148a increases glioma cell migration and invasion by downregulating GADD45A in human gliomas with IDH1 R132H mutations.
Glioma
Mitochondrial Dysfunction in Gliomas: Pharmacotherapeutic Potential of Natural Compounds.
Glioma
MLK3 Is Associated With Poor Prognosis in Patients With Glioblastomas and Actin Cytoskeleton Remodeling in Glioblastoma Cells.
Glioma
Molecular and clinical characterization of CD163 expression via large-scale analysis in glioma.
Glioma
Molecular and clinical characterization of IDH associated immune signature in lower-grade gliomas.
Glioma
Molecular and clinical characterization of PTPN2 expression from RNA-seq data of 996 brain gliomas.
Glioma
Molecular classification of IDH-mutant glioblastomas based on gene expression profiles.
Glioma
Molecular diagnostics of gliomas using next generation sequencing of a glioma-tailored gene panel.
Glioma
Molecular investigation of isocitrate dehydrogenase gene (IDH) mutations in gliomas: first report of IDH2 mutations in Indian patients.
Glioma
Molecular pathways in gliomagenesis and their relevance to neuropathologic diagnosis.
Glioma
Molecular subtypes, stem cells and heterogeneity: Implications for personalised therapy in glioma.
Glioma
Molecular subtyping reveals immune alterations in IDH wild-type lower-grade diffuse glioma.
Glioma
MR image phenotypes may add prognostic value to clinical features in IDH wild-type lower-grade gliomas.
Glioma
MR Imaging-derived Oxygen Metabolism and Neovascularization Characterization for Grading and IDH Gene Mutation Detection of Gliomas.
Glioma
MR spectroscopy for in vivo assessment of the oncometabolite 2-hydroxyglutarate and its effects on cellular metabolism in human brain gliomas at 9.4T.
Glioma
MRI and CT Identify Isocitrate Dehydrogenase (IDH)-Mutant Lower-Grade Gliomas Misclassified to 1p/19q Codeletion Status with Fluorescence in Situ Hybridization.
Glioma
MRI Features and IDH Mutational Status of Grade II Diffuse Gliomas: Impact on Diagnosis and Prognosis.
Glioma
MRI Features May Predict Molecular Features of Glioblastoma in Isocitrate Dehydrogenase Wild-Type Lower-Grade Gliomas.
Glioma
Multi-parametric Z-spectral MRI may have a good performance for glioma stratification in clinical patients.
Glioma
Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas.
Glioma
Multiparametric and multiregional diffusion features help predict molecule information, grade and survival in lower-grade gliomas: a feasibility study.
Glioma
Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas.
Glioma
Multiple positron emission tomography tracers for use in the classification of gliomas according to the 2016 World Health Organization criteria.
Glioma
Multivariable non-invasive association of isocitrate dehydrogenase mutational status in World Health Organization grade II and III gliomas with advanced magnetic resonance imaging T2 mapping techniques.
Glioma
Mutant IDH1 Expression Drives TERT Promoter Reactivation as Part of the Cellular Transformation Process.
Glioma
Mutant-allele tumor heterogeneity in malignant glioma effectively predicts neoplastic recurrence.
Glioma
Mutation of isocitrate dehydrogenase 1 induces glioma cell proliferation via nuclear factor??B activation in a hypoxia?inducible factor 1?? dependent manner.
Glioma
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.
Glioma
Mutations in isocitrate dehydrogenase 2 accelerate glioma cell migration via matrix metalloproteinase-2 and 9
Glioma
Mutations in isocitrate dehydrogenase 2 accelerate glioma cell migration via matrix metalloproteinase-2 and 9.
Glioma
Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in IDH-Mutant Lower Grade Gliomas.
Glioma
Non-invasive detection of 2-hydroxyglutarate in IDH-mutated gliomas using two-dimensional localized correlation spectroscopy (2D L-COSY) at 7 Tesla.
Glioma
Non-Invasive Estimation of Glioma IDH1 Mutation and VEGF Expression by Histogram Analysis of Dynamic Contrast-Enhanced MRI.
Glioma
Non-Invasive Prediction of IDH Mutation in Patients with Glioma WHO II/III/IV Based on F-18-FET PET-Guided In Vivo 1H-Magnetic Resonance Spectroscopy and Machine Learning.
Glioma
Noninvasive Assessment of IDH Mutational Status in World Health Organization Grade II and III Astrocytomas Using DWI and DSC-PWI Combined with Conventional MR Imaging.
Glioma
Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting.
Glioma
Noninvasive Determination of IDH and 1p19q Status of Lower-grade Gliomas Using MRI Radiomics: A Systematic Review.
Glioma
Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations.
Glioma
Noninvasively evaluating the grading and IDH1 mutation status of diffuse gliomas by three-dimensional pseudo-continuous arterial spin labeling and diffusion-weighted imaging.
Glioma
O(6)-methyl-guanine-DNA methyltransferase methylation and IDH1/2 mutation in small cell lung cancer.
Glioma
Oncogenic transgelin-2 is differentially regulated in isocitrate dehydrogenase wild-type vs. mutant gliomas.
Glioma
Oncogenic ZEB2/miR-637/HMGA1 signaling axis targeting vimentin promotes the malignant phenotype of glioma.
Glioma
Outcomes of salvage fractionated re-irradiation combined with bevacizumab for recurrent high-grade gliomas that progressed after bevacizumab treatment*.
Glioma
Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
Glioma
Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.
Glioma
Pathogenic Epigenetic Consequences of Genetic Alterations in IDH-wild-type Diffuse Astrocytic Gliomas.
Glioma
Pathologic diversity of glioneuronal tumor with neuropil-like islands: A histological and immunohistochemical study with a special reference to isocitrate dehydrogenase 1 (IDH1) in 5 cases.
Glioma
Patient-derived xenografts of different grade gliomas retain the heterogeneous histological and genetic features of human gliomas.
Glioma
PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations.
Glioma
PDIA3 correlates with clinical malignant features and immune signature in human gliomas.
Glioma
Perfusion MRI grading diffuse gliomas: Impact of permeability parameters on molecular biomarkers and survival.
Glioma
Peripheral blood test provides a practical method for glioma evaluation and prognosis prediction.
Glioma
Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.
Glioma
Pharmaco-transcriptomic correlation analysis reveals novel responsive signatures to HDAC inhibitors and identifies Dasatinib as a synergistic interactor in small-cell lung cancer.
Glioma
Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option?
Glioma
Practical implications of integrated glioma classification according to the World Health Organization classification of tumors of the central nervous system 2016.
Glioma
Pre-operative Neurocognitive Function Was More Susceptible to Decline in Isocitrate Dehydrogenase Wild-Type Subgroups of Lower-Grade Glioma Patients.
Glioma
Predicting 1p/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas.
Glioma
Predicting IDH mutation status in grade II gliomas using amide proton transfer-weighted (APTw) MRI.
Glioma
Predicting Isocitrate Dehydrogenase (IDH) Mutation Status in Gliomas Using Multiparameter MRI Radiomics Features.
Glioma
Predicting prognosis and IDH mutation status for patients with lower-grade gliomas using whole slide images.
Glioma
Prediction of IDH genotype in gliomas with dynamic susceptibility contrast perfusion MR imaging using an explainable recurrent neural network.
Glioma
Prediction of IDH Mutation Status in High-grade Gliomas Using DWI and High T1-weight DSC-MRI.
Glioma
Prediction of IDH Status Through MRI Features and Enlightened Reflection on the Delineation of Target Volume in Low-Grade Gliomas.
Glioma
Prediction of Isocitrate Dehydrogenase Genotype in Brain Gliomas with MRI: Single-Shell versus Multishell Diffusion Models.
Glioma
Prediction of Overall Survival Based on Isocitrate Dehydrogenase 1 Mutation and 18F-FDG Uptake on PET/CT in Patients With Cerebral Gliomas.
Glioma
Predictive Role of the Apparent Diffusion Coefficient and MRI Morphologic Features on IDH Status in Patients With Diffuse Glioma: A Retrospective Cross-Sectional Study.
Glioma
Preoperative Changes in Hematological Markers and Predictors of Glioma Grade and Survival.
Glioma
Preoperative Determination of Isocitrate Dehydrogenase Mutation in Gliomas Using Spectral Editing MRS: A Prospective Study.
Glioma
Primary orthotopic glioma xenografts recapitulate infiltrative growth and isocitrate dehydrogenase I mutation.
Glioma
Production of 2-hydroxyglutarate by isocitrate dehydrogenase 1-mutated gliomas: an evolutionary alternative to the Warburg shift?
Glioma
Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.
Glioma
Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
Glioma
Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis.
Glioma
Prognostic Value of Preoperative MRI Metrics for Diffuse Lower-Grade Glioma Molecular Subtypes.
Glioma
Protein disulphide isomerase can predict the clinical prognostic value and contribute to malignant progression in gliomas.
Glioma
PSMA Expression in 122 Treatment Naive Glioma Patients Related to Tumor Metabolism in 11C-Methionine PET and Survival.
Glioma
Pyrosequencing of IDH1 and IDH2 mutations in brain tumors and non-neoplastic conditions.
Glioma
Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients.
Glioma
Radiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II and III gliomas.
Glioma
Radiological differences between subtypes of WHO 2016 grade II-III gliomas: a systematic review and meta-analysis.
Glioma
Radiomics risk score may be a potential imaging biomarker for predicting survival in isocitrate dehydrogenase wild-type lower-grade gliomas.
Glioma
Radiomics Strategy for Molecular Subtype Stratification of Lower-Grade Glioma: Detecting IDH and TP53 Mutations Based on Multimodal MRI.
Glioma
Radiomics-based machine learning methods for isocitrate dehydrogenase genotype prediction of diffuse gliomas.
Glioma
Raman Spectroscopy and Machine Learning for IDH Genotyping of Unprocessed Glioma Biopsies.
Glioma
Rapid determination of isocitrate dehydrogenase mutation status of human gliomas by extraction nanoelectrospray using a miniature mass spectrometer.
Glioma
Rapid diagnosis of IDH1-mutated gliomas by 2-HG detection with gas chromatography mass spectrometry.
Glioma
Rapid intraoperative molecular genetic classification of gliomas using Raman spectroscopy.
Glioma
Recent Developments and Future Directions in Adult Lower-Grade Gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) Consensus.
Glioma
Receptor tyrosine kinase expression in high-grade gliomas before and after chemoradiotherapy.
Glioma
Reducing radiation dose to normal brain through a risk adapted dose reduction protocol for patients with favourable subtype anaplastic glioma.
Glioma
Reflecting on survivorship outcomes to aid initial decision making in patients treated for IDH-mutated anaplastic glioma.
Glioma
Regional and Volumetric Parameters for Diffusion-Weighted WHO Grade II and III Glioma Genotyping: A Method Comparison.
Glioma
Relationship of Molecular Genetic Tumor Marker IDH with Oxidative Status in Gliomas.
Glioma
Relaxometry and quantification in sodium MRI of cerebral gliomas: A FET-PET and MRI small-scale study.
Glioma
Reliable diagnosis of IDH-mutant glioblastoma by 2-hydroxyglutarate detection: a study by 3-T magnetic resonance spectroscopy.
Glioma
Ribosomal Protein S27/Metallopanstimulin-1 (RPS27) in Glioma-A New Disease Biomarker?
Glioma
RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
Glioma
Role of traditional CHO PET parameters in distinguishing IDH, TERT and MGMT alterations in primary diffuse gliomas.
Glioma
Rosette-Forming Glioneuronal Tumor Originating From the Spinal Cord: Report of 2 Cases and Literature Review.
Glioma
RUNX1 and REXO2 are associated with the heterogeneity and prognosis of IDH wild type lower grade glioma.
Glioma
Selective detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of glioma patients with mutated Isocitrate Dehydrogenase.
Glioma
Silencing of mitochondrial NADP(+)-dependent isocitrate dehydrogenase gene enhances glioma radiosensitivity.
Glioma
Single-nucleus chromatin accessibility reveals intratumoral epigenetic heterogeneity in IDH1 mutant gliomas.
Glioma
Six-Transmembrane Epithelial Antigen of Prostate 3 Predicts Poor Prognosis and Promotes Glioblastoma Growth and Invasion.
Glioma
Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
Glioma
Static 18F-FET PET and DSC-PWI based on hybrid PET/MR for the prediction of gliomas defined by IDH and 1p/19q status.
Glioma
Structure based discovery of clomifene as a potent inhibitor of cancer-associated mutant IDH1.
Glioma
Super-Resolution Whole-Brain 3D MR Spectroscopic Imaging for Mapping D-2-Hydroxyglutarate and Tumor Metabolism in Isocitrate Dehydrogenase 1-mutated Human Gliomas.
Glioma
Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status.
Glioma
Synthesis and Comparative In Vivo Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPET.
Glioma
Synthesis and Evaluation of a 18F-Labeled Triazinediamine Analogue for Imaging Mutant IDH1 Expression in Gliomas by PET.
Glioma
T2 mapping of the peritumoral infiltration zone of glioblastoma and anaplastic astrocytoma.
Glioma
T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology.
Glioma
Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.
Glioma
Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.
Glioma
Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
Glioma
Ten-Eleven Translocation-2 gene mutations: A potential new molecular marker in malignant gliomas (Review).
Glioma
TERT Mutation Is Accompanied by Neutrophil Infiltration and Contributes to Poor Survival in Isocitrate Dehydrogenase Wild-Type Glioma.
Glioma
TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.
Glioma
The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision.
Glioma
The association between 11C-methionine uptake, IDH gene mutation, and MGMT promoter methylation in patients with grade II and III gliomas.
Glioma
The chemokine receptor CXCR7 influences prognosis in human glioma in an IDH1-dependent manner.
Glioma
The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study.
Glioma
The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas.
Glioma
The Correlation of Fluorescence of Protoporphyrinogen IX and Status of Isocitrate Dehydrogenase in Gliomas.
Glioma
The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas.
Glioma
The emerging role of d-2-hydroxyglutarate as an oncometabolite in hematolymphoid and central nervous system neoplasms.
Glioma
The glutamine antagonist prodrug JHU-083 slows malignant glioma growth and disrupts mTOR signaling.
Glioma
The hypermethylation of the O6-methylguanine-DNA methyltransferase gene promoter in gliomas--correlation with array comparative genome hybridization results and IDH1 mutation.
Glioma
The impact of body mass index and height on the risk for glioblastoma and other glioma subgroups: a large prospective cohort study.
Glioma
The presence of TIM-3 positive cells in WHO grade III and IV astrocytic gliomas correlates with isocitrate dehydrogenase mutation status.
Glioma
The R132H mutation in IDH1 promotes the recruitment of NK cells through CX3CL1/CX3CR1 chemotaxis and is correlated with a better prognosis in gliomas.
Glioma
The role of 2-hydroxyglutarate magnetic resonance spectroscopy for the determination of isocitrate dehydrogenase status in lower grade gliomas versus glioblastoma: a systematic review and meta-analysis of diagnostic test accuracy.
Glioma
The Role of the T2-FLAIR Mismatch Sign as an Imaging Marker of IDH Status in a Mixed Population of Low- and High-Grade Gliomas.
Glioma
The T2-FLAIR mismatch sign as a predictor of IDH-mutant, 1p/19q-noncodeleted lower-grade gliomas: a systematic review and diagnostic meta-analysis.
Glioma
The T2-FLAIR Mismatch Sign as an Imaging Marker for Non-Enhancing IDH-mutant, 1p/19q-intact Lower Grade Glioma: A Validation Study.
Glioma
The Updated World Health Organization Glioma Classification: Cellular and Molecular Origins of Adult Infiltrating Gliomas.
Glioma
Tissue 2-hydroxyglutarate as a biomarker for isocitrate dehydrogenase (IDH) mutations in gliomas.
Glioma
To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma.
Glioma
To treat or not to treat? A retrospective multicenter assessment of survival in patients with IDH-mutant low-grade glioma based on adjuvant treatment.
Glioma
Transcriptional alterations in glioma result primarily from DNA methylation-independent mechanisms.
Glioma
Transcriptional Characteristics of IDH-Wild Type Glioma Subgroups Highlight the Biological Processes Underlying Heterogeneity of IDH-Wild Type WHO Grade IV Gliomas.
Glioma
Transcriptomic Analysis of Glioma Based on IDH Status Identifies ACAA2 as a Prognostic Factor in Lower Grade Glioma.
Glioma
Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate.
Glioma
Tumour volume reduction following PET guided intensity modulated radiation therapy and temozolomide in IDH mutated anaplastic glioma.
Glioma
Ultra-high-field sodium MRI as biomarker for tumor extent, grade and IDH mutation status in glioma patients.
Glioma
Vessel Size Imaging is Associated with IDH Mutation and Patient Survival in Diffuse Lower-Grade Glioma.
Glioma
Volumetric Analysis of IDH-Mutant Lower-Grade Glioma: A Natural History Study of Tumor Growth Rates Before and After Treatment.
Glioma
Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients.
Glioma
Voxel-wise radiogenomic mapping of tumor location with key molecular alterations in patients with glioma.
Glioma
Widely metastatic IDH1-mutant glioblastoma with oligodendroglial features and atypical molecular findings: a case report and review of current challenges in molecular diagnostics.
Glioma
Widespread overexpression from the four DNA hypermethylated HOX clusters in aggressive (IDHwt) glioma is associated with H3K27me3 depletion and alternative promoter usage.
Glioma
World Health Organization Grade II/III Glioma Molecular Status: Prediction by MRI Morphologic Features and Apparent Diffusion Coefficient.
Glioma
Worse prognosis for IDH wild-type diffuse gliomas with larger residual biological tumor burden.
Glioma
[Analysis of the clinical impact of the diagnostic reclassification of brain gliomas according to the World Health Organization classification (2016)].
Glioma
[Clinicopathological and molecular genetic characteristics of adult IDH wild-type diffuse gliomas].
Glioma
[IDH mutations activate Hoxa9/Meis1 and hypoxia pathways in acute myeloid leukemia model mice].
Glioma
[Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors. German version].
Glioma
[The expression of IDH1 (R132H) is positively correlated with cell proliferation and angiogenesis in glioma samples].
Gliosarcoma
Analysis of the effect of photodynamic therapy with Fotoenticine on gliosarcoma cells.
Head and Neck Neoplasms
Targeting metabolic pathways for head and neck cancers therapeutics.
Heart Failure
Proteomic analysis of left ventricular remodeling in an experimental model of heart failure.
Hemangioma
Somatic mosaic mutations of IDH1 and NPM1 associated with cup-like acute myeloid leukemia in a patient with Maffucci syndrome.
Hematologic Neoplasms
Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm.
Hematologic Neoplasms
IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
Hematologic Neoplasms
Isocitrate Dehydrogenase 2 Inhibitors for the Treatment of Hematologic Malignancies: Advances and Future Opportunities.
Hematologic Neoplasms
Mathematical analysis predicts imbalanced IDH1/2 expression associates with 2-HG-inactivating ?-oxygenation pathway in colorectal cancer.
Hematologic Neoplasms
Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics.
Hematologic Neoplasms
Quantitation of isocitrate dehydrogenase (IDH)-induced D and L enantiomers of 2-hydroxyglutaric acid in biological fluids by a fully validated liquid tandem mass spectrometry method, suitable for clinical applications.
Hepatitis
HIGH SERUM TRANSAMINASE AND ISOCITRIC DEHYDROGENASE LEVELS IN A PATIENT WITH CHOLECYSTITIS AND SUBACUTE HEPATITIS.
Hepatitis
Plasma isocitrate dehydrogenase as a marker of centrilobular hepatic necrosis in patients with hyperthyroidism.
Hepatitis
[Activity of liver mitochondrial NAD+-dependent dehydrogenases of the krebs cycle in rats with acetaminophen-induced hepatitis developed under conditions of alimentary protein deficiency].
Hepatitis
[Behavior of serum isocitrate dehydrogenase in subjects with viral hepatitis after treatment with lysozyme]
Hepatitis
[Study on the behavior of serum isocitrate dehydrogenase. In subjects affected by viral hepatitis]
Hepatitis
[The value of isocitric dehydrogenase in the differential diagnosis between viral hepatitis and Weil's disease.]
Hepatitis A
Comparison of activities of isocitric dehydrogenase and glutamic-oxalacetic transaminase in serum infectious hepatitis.
Herpes Simplex
Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma.
Hidradenitis Suppurativa
Reduced ten-eleven translocation and isocitrate dehydrogenase expression in inflammatory hidradenitis suppurativa lesions.
Hydrocephalus
Prognostic Value of Preoperative MRI Metrics for Diffuse Lower-Grade Glioma Molecular Subtypes.
Hyperglycemia
Metformin counteracts glucose-dependent lipogenesis and impairs transdeamination in the liver of gilthead sea bream (Sparus aurata).
Hyperhomocysteinemia
Homocysteine induces energy imbalance in rat skeletal muscle: Is creatine a protector?
Hypersensitivity
Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.
Hypertension
Comparative analysis of renal protein expression in spontaneously hypertensive rat.
Hypertension
Isocitrate dehydrogenase 2 deficiency aggravates prolonged high-fat diet intake-induced hypertension.
Hyperthyroidism
Plasma isocitrate dehydrogenase as a marker of centrilobular hepatic necrosis in patients with hyperthyroidism.
Hypoglycemia
Cocklebur (Xanthium strumarium, L. var. strumarium) intoxication in swine: review and redefinition of the toxic principle.
Hypokinesia
[Activity of oxidative enzymes of the tricarboxylic acid cycle in the liver of rats during hypokinesia]
Hypokinesia
[Oxidative enzyme activity of the tricarboxylic acid cycle in rat skeletal muscles in hypokinesia]
Infections
Acute GB virus B infection of marmosets is accompanied by mutations in the NS5A protein.
Infections
Alterations in enzymatic activities of the intestinal mucosa during the course of Giardia lamblia infection in mice.
Infections
Alterations in metabolic pathways in gastric epithelial cells infected with Helicobacter pylori.
Infections
Comparative proteome analysis of splenic lymphocytes in senescence-accelerated mice.
Infections
Further investigations of race:cultivar-specific induction of enzymes related to phytoalexin biosynthesis in soybean roots following infection with Phytophthora megasperma f.sp. glycinea.
Influenza, Human
Structural similarity between binding sites in influenza sialidase and isocitrate dehydrogenase: implications for an alternative approach to rational drug design.
Insulin Resistance
Increased obesity resistance and insulin sensitivity in mice lacking the isocitrate dehydrogenase 2 gene.
Intellectual Disability
In Vivo Molecular Profiling of Human Glioma : Cross-Sectional Observational Study Using Dynamic Susceptibility Contrast Magnetic Resonance Perfusion Imaging.
Intellectual Disability
Interstitial deletion of the long arm of chromosome 2 with normal levels of isocitrate dehydrogenase.
Intellectual Disability
Main genetic differences in high-grade gliomas may present different MR imaging and MR spectroscopy correlates.
Iron Deficiencies
Bio-inorganic regulation of pathways of carbohydrate and lipid metabolism. II. The effect of iron-deficiency on the profile of enzymes in the developing rat adrenal gland.
Iron Deficiencies
Perturbation of mitochondrial composition in muscle by iron deficiency. Implications regarding regulation of mitochondrial assembly.
isocitrate dehydrogenase (nad+) deficiency
Isocitrate dehydrogenase 2 deficiency aggravates prolonged high-fat diet intake-induced hypertension.
isocitrate dehydrogenase (nad+) deficiency
Isocitrate dehydrogenase 2 deficiency exacerbates dermis damage by ultraviolet-B via ?Np63 downregulation.
isocitrate dehydrogenase (nad+) deficiency
Isocitrate dehydrogenase 2 deficiency induces endothelial inflammation via p66sh-mediated mitochondrial oxidative stress.
isocitrate dehydrogenase (nad+) deficiency
Mitochondrial NADP(+)-Dependent Isocitrate Dehydrogenase Deficiency Exacerbates Mitochondrial and Cell Damage after Kidney Ischemia-Reperfusion Injury.
Leber Congenital Amaurosis
A novel variant in IDH3A identified in a case with Leber congenital amaurosis accompanied by macular pseudocoloboma.
Leukemia
Alterations of Mitochondria and Related Metabolic Pathways in Leukemia: A Narrative Review.
Leukemia
ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia.
Leukemia
Differentiation syndrome during ivosidenib treatment with immunohistochemistry showing isocitrate dehydrogenase R132H mutation.
Leukemia
Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations.
Leukemia
Genetic dissection of leukemia-associated IDH1 and IDH2 mutants and D-2-hydroxyglutarate in Drosophila.
Leukemia
Genistein decreases cellular redox potential, partially suppresses cell growth in HL?60 leukemia cells and sensitizes cells to ??radiation?induced cell death.
Leukemia
IDH mutations associated impact on related cancer epidemiology and subsequent effect toward HIF-1?.
Leukemia
IDH2 reprograms mitochondrial dynamics in cancer through a HIF-1?-regulated pseudohypoxic state.
Leukemia
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
Leukemia
Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.
Leukemia
Transcriptome Analysis of Ivosidenib-Mediated Inhibitory Functions on Non-Small Cell Lung Cancer.
Leukemia
[Behavior of serum isocitrate dehydrogenase in acute lymphatic leukemia of childhood]
Leukemia, Myeloid
IDH Mutation Detection in Formalin-Fixed Paraffin-Embedded Gliomas Using Multiplex PCR and Single-base Extension.
Leukemia, Myeloid
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.
Leukemia, Myeloid, Acute
2-hydroxyglutarate as a magnetic resonance biomarker for glioma subtyping.
Leukemia, Myeloid, Acute
A high-throughput analysis of the IDH1(R132H) protein expression in pituitary adenomas.
Leukemia, Myeloid, Acute
A novel monoclonal antibody SMab-2 recognizes endogenous IDH2-R172S of chondrosarcoma.
Leukemia, Myeloid, Acute
A Rare Case of Systemic Mastocytosis With Associated Clonal Hematological Non-Mast Cell Lineage Disease That Transformed to Acute Leukemia With IDH2 Mutation.
Leukemia, Myeloid, Acute
A synthetic lethal approach targeting mutant isocitrate dehydrogenase in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Acquired somatic mutations of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) in preleukemic disorders.
Leukemia, Myeloid, Acute
Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm.
Leukemia, Myeloid, Acute
ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia.
Leukemia, Myeloid, Acute
Assessing acquired resistance to IDH1 inhibitor therapy by full-exon IDH1 sequencing and structural modeling.
Leukemia, Myeloid, Acute
Association of The IDH1 C.395G>A (R132H) Mutation with Histological Type in Malay Brain Tumors
Leukemia, Myeloid, Acute
Bone Marrow Features in Patients With Acute Myeloid Leukemia Treated With Novel Targeted Isocitrate Dehydrogenase 1/2 Inhibitors.
Leukemia, Myeloid, Acute
Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation.
Leukemia, Myeloid, Acute
Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition.
Leukemia, Myeloid, Acute
CBFB-MYH11 Fusion Sequesters RUNX1 in Cytoplasm to Prevent DNMT3A Recruitment to Target Genes in AML.
Leukemia, Myeloid, Acute
Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
Leukemia, Myeloid, Acute
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.
Leukemia, Myeloid, Acute
Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms.
Leukemia, Myeloid, Acute
Correlation Between Isocitrate Dehydrogenase Gene Aberrations and Prognosis of Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.
Leukemia, Myeloid, Acute
Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.
Leukemia, Myeloid, Acute
Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase.
Leukemia, Myeloid, Acute
D-2-hydroxyglutarate interferes with HIF-1? stability skewing T-cell metabolism towards oxidative phosphorylation and impairing Th17 polarization.
Leukemia, Myeloid, Acute
Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients.
Leukemia, Myeloid, Acute
Differentiating the Differentiation Syndrome Associated with IDH Inhibitors in AML.
Leukemia, Myeloid, Acute
Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.
Leukemia, Myeloid, Acute
Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis.
Leukemia, Myeloid, Acute
Enasidenib drives human erythroid differentiation independently of isocitrate dehydrogenase 2.
Leukemia, Myeloid, Acute
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.
Leukemia, Myeloid, Acute
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.
Leukemia, Myeloid, Acute
Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.
Leukemia, Myeloid, Acute
FDA Approval Summary: Ivosidenib for relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-1 mutation.
Leukemia, Myeloid, Acute
Frequent IDH1/2 mutations in intracranial chondrosarcoma: a possible diagnostic clue for its differentiation from chordoma.
Leukemia, Myeloid, Acute
Generation of a novel monoclonal antibody WMab-1 specific for IDH2-R172W mutation.
Leukemia, Myeloid, Acute
Genome-scale integrated analysis to identify prospective molecular mechanisms and therapeutic targets in isocitrate dehydrogenase 2 R140Q-mutated acute myeloid leukemia.
Leukemia, Myeloid, Acute
Identification of High-Affinity Small Molecule Targeting IDH2 for the Clinical Treatment of Acute Myeloid Leukemia.
Leukemia, Myeloid, Acute
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
Leukemia, Myeloid, Acute
IDH1 mutation contributes to myeloid dysplasia in mice by disturbing heme biosynthesis and erythropoiesis.
Leukemia, Myeloid, Acute
IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.
Leukemia, Myeloid, Acute
IDH2 compensates for IDH1 mutation to maintain cell survival under hypoxic conditions in IDH1?mutant tumor cells.
Leukemia, Myeloid, Acute
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.
Leukemia, Myeloid, Acute
Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis.
Leukemia, Myeloid, Acute
Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm.
Leukemia, Myeloid, Acute
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia.
Leukemia, Myeloid, Acute
Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1.
Leukemia, Myeloid, Acute
Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.
Leukemia, Myeloid, Acute
Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone.
Leukemia, Myeloid, Acute
Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes and in Acute Myeloid Leukemias.
Leukemia, Myeloid, Acute
JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition.
Leukemia, Myeloid, Acute
Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells.
Leukemia, Myeloid, Acute
Molecular Pathways: Mitochondrial Reprogramming in Tumor Progression and Therapy.
Leukemia, Myeloid, Acute
Mutation Analysis of Isocitrate Dehydrogenase (IDH1/2) and DNA Methyltransferase 3A (DNMT3A) in Thai Patients with Newly Diagnosed Acute Myeloid Leukemia
Leukemia, Myeloid, Acute
Mutation analysis of isocitrate dehydrogenase in acute lymphoblastic leukemia.
Leukemia, Myeloid, Acute
Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C?>?T have a prognostic value in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models.
Leukemia, Myeloid, Acute
Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.
Leukemia, Myeloid, Acute
Persistence of mutant isocitrate dehydrogenase in patients with acute myeloid leukemia in remission.
Leukemia, Myeloid, Acute
Potent immunosuppressive effects of the oncometabolite R-2-hydroxyglutarate.
Leukemia, Myeloid, Acute
Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis.
Leukemia, Myeloid, Acute
Potential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancers.
Leukemia, Myeloid, Acute
Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia.
Leukemia, Myeloid, Acute
Prevalence and Clinical Effect of IDH1 and IDH2 Mutations Among Cytogenetically Normal Acute Myeloid Leukemia Patients.
Leukemia, Myeloid, Acute
Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups.
Leukemia, Myeloid, Acute
Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.
Leukemia, Myeloid, Acute
Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study.
Leukemia, Myeloid, Acute
Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response.
Leukemia, Myeloid, Acute
Quantification of 2-Hydroxyglutarate Enantiomers by Liquid Chromatography-mass Spectrometry.
Leukemia, Myeloid, Acute
Rapid detection of IDH2 (R140Q and R172K) mutations in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Real-world assessment of isocitrate dehydrogenase inhibitor-associated differentiation syndrome.
Leukemia, Myeloid, Acute
Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Leukemia, Myeloid, Acute
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.
Leukemia, Myeloid, Acute
SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML.
Leukemia, Myeloid, Acute
SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.
Leukemia, Myeloid, Acute
Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
Leukemia, Myeloid, Acute
Steroids from Ganoderma sinense as new natural inhibitors of cancer-associated mutant IDH1.
Leukemia, Myeloid, Acute
Structure based discovery of clomifene as a potent inhibitor of cancer-associated mutant IDH1.
Leukemia, Myeloid, Acute
Structure-based design, synthesis and bioactivity evaluation of macrocyclic inhibitors of mutant isocitrate dehydrogenase 2 (IDH2) displaying activity in acute myeloid leukemia cells.
Leukemia, Myeloid, Acute
The emerging role of d-2-hydroxyglutarate as an oncometabolite in hematolymphoid and central nervous system neoplasms.
Leukemia, Myeloid, Acute
The long non-coding RNA Cancer Susceptibility 15 (CASC15) is induced by isocitrate dehydrogenase (IDH) mutations and maintains an immature phenotype in adult acute myeloid leukemia.
Leukemia, Myeloid, Acute
The long non-coding RNA Cancer Susceptibility 15 is induced by Isocitrate Dehydrogenase mutations and maintains an immature phenotype in adult acute myeloid leukemia.
Leukemia, Myeloid, Acute
The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia.
Leukemia, Myeloid, Acute
The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status.
Leukemia, Myeloid, Acute
The prognostic significance of IDH2 mutations in AML depends on the location of the mutation.
Leukemia, Myeloid, Acute
The role of autophagy in targeted therapy for acute myeloid leukemia.
Leukemia, Myeloid, Acute
The Synonymous Isocitrate Dehydrogenase 1 315C>T SNP Confers an Adverse Prognosis in Egyptian Adult Patients with NPM1-/CEBPA-Negative Acute Myeloid Leukemia.
Leukemia, Myeloid, Acute
Thyroiditis: A Rare Manifestation of Enasidenib-Induced Differentiation Syndrome.
Leukemia, Myeloid, Acute
Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia.
Leukemia, Myeloid, Acute
Validated HPLC method for simultaneous quantification of mutant IDH1/2 inhibitors (enasidenib, ivosidenib and vorasidenib) in mouse plasma: Application to a pharmacokinetic study.
Leukemia, Myeloid, Acute
Validated LC-MS/MS Method for Simultaneous Quantitation of Enasidenib and its Active Metabolite, AGI-16903 in Small Volume Mice Plasma: Application to a Pharmacokinetic Study.
Leukemia, Myeloid, Acute
[Clinical characteristics in adult acute myeloid leukemia with isocitrate dehydrogenase gene mutation].
Leukemia, Myeloid, Acute
[IDH mutations activate Hoxa9/Meis1 and hypoxia pathways in acute myeloid leukemia model mice].
Leukemia, Myeloid, Acute
[Mutation of isocitrate dehydrogenase 2 (IDH2) gene in Chinese AML patients and its clinical significance].
Leukemia, Promyelocytic, Acute
ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia.
Leukemia, Promyelocytic, Acute
The role of autophagy in targeted therapy for acute myeloid leukemia.
Leukocytosis
Identification of High-Affinity Small Molecule Targeting IDH2 for the Clinical Treatment of Acute Myeloid Leukemia.
Lipid Metabolism Disorders
[The role of lipid metabolism disorders, atypical isoforms of protein kinase C, and mutational status of cytosolic and mitochondrial forms of isocitrate dehydrogenase in carcinogenesis of glial tumors].
Liver Diseases
Falsely normal value in fluorometric transferase screening of galactosemic blood. A cautionary note.
Liver Diseases
Serum isocitric dehydrogenase activity in the differential diagnosis of liver disease.
Liver Diseases
Serum isocitric dehydrogenase activity with particular reference to liver disease.
Liver Diseases
[SERUM ENZYMES IN THE DIAGNOSIS OF LIVER DISEASE. III. SORBITOL DEHYDROGENASE, ALDOLASES, ISOCITRIC DEHYDROGENASE AND TRANSAMINASES.]
Liver Diseases
[Studies on the enzymatic activity value of serum isocitrate dehydrogenase in pediatrics. 3. On the enzymatic activity value of serum isocitrate dehydrogenase in liver diseases in children.]
Liver Diseases
[The diagnostic importance of isocitrate dehydrogenase and of glutathione reductase in liver diseases.]
Lung Neoplasms
Effect of mangiferin on benzo(a)pyrene induced lung carcinogenesis in experimental Swiss albino mice.
Lung Neoplasms
IDH-Inhibiting Small Molecule DTDQ Inhibits Migration and Invasion of A549 Human Non-Small-Cell Lung Cancer Cells via Sequential Inactivation Of ERK and P38 Signaling Pathways.
Lung Neoplasms
Modulation of TCA cycle enzymes and electron transport chain systems in experimental lung cancer.
Lung Neoplasms
Pharmaco-transcriptomic correlation analysis reveals novel responsive signatures to HDAC inhibitors and identifies Dasatinib as a synergistic interactor in small-cell lung cancer.
Lung Neoplasms
Pharmacotranscriptomic Analysis Reveals Novel Drugs and Gene Networks Regulating Ferroptosis in Cancer.
Lung Neoplasms
Synthesis and Comparative In Vivo Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPET.
Lung Neoplasms
Weak sharing of genetic association signals in three lung cancer subtypes: evidence at the SNP, gene, regulation, and pathway levels.
Lung Neoplasms
[Value of Serum Tumor Marker Isocitrate Dehydrogenase 1 in the Diagnosis of Lung Cancer].
Lymphoma
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
Lymphoma, B-Cell
New directions for emerging therapies in acute myeloid leukemia: the next chapter.
Lymphoma, B-Cell
Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment.
Lymphoma, T-Cell
Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms.
Lymphoma, T-Cell, Peripheral
Identification of cell-type-specific mutations in nodal T-cell lymphomas.
Malaria
NADP-specific isocitrate dehydrogenase from the simian malaria parasite Plasmodium knowlesi: partial purification and characterization.
Malnutrition
[Activity of amylase, lipase and isocitrate dehydrogenase enzymes in cases of proteino-caloric malnutrition]
Medulloblastoma
The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision.
Melanoma
5-Hydroxymethylcytosine Expression in Proliferative Nodules Arising within Congenital Nevi Allows Differentiation from Malignant Melanoma.
Melanoma
A Rare Case of Atypical Pleomorphic Neoplasm of Pineal Region in a Child: A Case Report.
Melanoma
Elucidation of the TMab-6 Monoclonal Antibody Epitope Against Telomerase Reverse Transcriptase.
Melanoma
Mitochondrial NADP(+)-dependent isocitrate dehydrogenase knockdown inhibits tumorigenicity of melanoma cells.
Melanoma
Proteomic investigation of the sinulariolide-treated melanoma cells A375: effects on the cell apoptosis through mitochondrial-related pathway and activation of caspase cascade.
Meningitis
Isocitric dehydrogenase of the cerebrospinal fluid in brain tumours and meningitis.
Microcephaly
Interstitial deletion of the long arm of chromosome 2 with normal levels of isocitrate dehydrogenase.
Mouth Neoplasms
Isocitrate dehydrogenase mutation hot spots in acute lymphoblastic leukemia and oral cancer.
Multiple Sclerosis
[DETERMINATION OF ISOCITRATE DEHYDROGENASE, LACTIC DEHYDROGENASE AND GLUTAMIC-OXALACETIC TRANSAMINASE IN THE CEREBROSPINAL FLUID IN MULTIPLE SCLEROSIS.]
Muscle Hypotonia
IDH1 mutated acute myeloid leukemia in a child with metaphyseal chondromatosis with D-2-hydroxyglutaric aciduria.
Muscular Dystrophy, Duchenne
[Reevaluation of serum isocitrate dehydrogenase concentration as liver function marker in patients with Duchenne muscular dystrophy]
Myelodysplastic Syndromes
Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients.
Myelodysplastic Syndromes
IDH1 mutation contributes to myeloid dysplasia in mice by disturbing heme biosynthesis and erythropoiesis.
Myelodysplastic Syndromes
Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes.
Myelodysplastic Syndromes
Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes and in Acute Myeloid Leukemias.
Myelodysplastic Syndromes
Methylation level of Rap1GAP and the clinical significance in MDS.
Myelodysplastic Syndromes
Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis.
Myelodysplastic Syndromes
The role of autophagy in targeted therapy for acute myeloid leukemia.
Myelodysplastic Syndromes
The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia.
Myelodysplastic Syndromes
[Relationship between clinical characteristics and myelodysplastic syndrome patients with isocitrate dehydrogenase gene mutations].
Myocardial Infarction
Resveratrol protects left ventricle by increasing adenylate kinase and isocitrate dehydrogenase activities in rats with myocardial infarction.
Myocarditis
[The effect of guanosyl-5'-monophosphate on metabolic processes in rats with experimental myocarditis]
Neoplasm Metastasis
Identification of a Glycolysis-Related LncRNA Signature to Predict Survival in Diffuse Glioma Patients.
Neoplasm Metastasis
Isocitrate dehydrogenase 3A, a rate-limiting enzyme of the TCA cycle, promotes hepatocellular carcinoma migration and invasion through regulation of MTA1, a core component of the NuRD complex.
Neoplasm, Residual
Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.
Neoplasms
18F-FET PET imaging in differentiating glioma progression from treatment-related changes - a single-center experience.
Neoplasms
18F-Fluorocholine PET/CT in the Prediction of Molecular Subtypes and Prognosis for Gliomas.
Neoplasms
A comprehensive review of available omics data resources and molecular profiling for precision glioma studies.
Neoplasms
A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults.
Neoplasms
A Hematological-Related Prognostic Scoring System for Patients With Newly Diagnosed Glioblastoma.
Neoplasms
A high-throughput analysis of the IDH1(R132H) protein expression in pituitary adenomas.
Neoplasms
A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor.
Neoplasms
A highly facile and specific assay for cancer-causing isocitrate dehydrogenase mutant using 13C4-labeled ?-ketoglutarate and heteronuclear NMR.
Neoplasms
A machine learning-based survival prediction model of high grade glioma by integration of clinical and dose-volume histogram parameters.
Neoplasms
A novel monoclonal antibody SMab-2 recognizes endogenous IDH2-R172S of chondrosarcoma.
Neoplasms
A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model.
Neoplasms
A Prognostic Microenvironment-Related Immune Signature via ESTIMATE (PROMISE Model) Predicts Overall Survival of Patients With Glioma.
Neoplasms
A Rare Case of Atypical Pleomorphic Neoplasm of Pineal Region in a Child: A Case Report.
Neoplasms
Aberrant IDH3? expression promotes malignant tumor growth by inducing HIF-1-mediated metabolic reprogramming and angiogenesis.
Neoplasms
Abnormally high expression of HOXA2 as an independent factor for poor prognosis in glioma patients.
Neoplasms
Absence of DICER1, CTCF, RPL22, DNMT3A, TRRAP, IDH1 and IDH2 hotspot mutations in patients with various subtypes of ovarian carcinomas.
Neoplasms
Absence of R140Q mutation of isocitrate dehydrogenase 2 in gliomas and breast cancers.
Neoplasms
Activated leukocyte cell adhesion molecule is expressed in neuroepithelial neoplasms and decreases with tumor malignancy, matrix metalloproteinase 2 expression, and absence of IDH1R132H mutation.
Neoplasms
Adjunctive markers for classification and diagnosis of central nervous system tumors: results of a multi-center neuropathological survey in Korea.
Neoplasms
Advances in genetic and epigenetic analyses of gliomas: a neuropathological perspective.
Neoplasms
Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide.
Neoplasms
Allosteric inhibitor remotely modulates the conformation of the orthestric pockets in mutant IDH2/R140Q.
Neoplasms
Alpha Internexin: A Surrogate Marker for 1p/19q Codeletion and Prognostic Marker in Anaplastic (WHO grade III) Gliomas.
Neoplasms
Altered Motor Excitability in Patients With Diffuse Gliomas Involving Motor Eloquent Areas: The Impact of Tumor Grading.
Neoplasms
An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival.
Neoplasms
An update of molecular pathology of bone tumors. Lessons learned from investigating samples by next generation sequencing.
Neoplasms
Analysis of Cellular Feature Differences of Astrocytomas with Distinct Mutational Profiles Using Digitized Histopathology Images.
Neoplasms
Analysis of Isocitrate Dehydrogenase -2 (IDH-2) Activity in Human Serum as a Biomarker in Chemotherapy Patients of Breast Carcinoma: A Case-Control Study.
Neoplasms
Analysis of Mutant Isocitrate Dehydrogenase 1 Immunoexpression, Ki-67 and Programmed Death Ligand 1 in Diffuse Astrocytic Tumours : Study of Single Center in Bandung, Indonesia.
Neoplasms
Analysis of the effect of photodynamic therapy with Fotoenticine on gliosarcoma cells.
Neoplasms
Anatomical, histomorphological and molecular classification of cholangiocarcinoma.
Neoplasms
Association between Tumor Acidity and Hypervascularity in Human Gliomas Using pH-Weighted Amine Chemical Exchange Saturation Transfer Echo-Planar Imaging and Dynamic Susceptibility Contrast Perfusion MRI at 3T.
Neoplasms
Association of dynamic susceptibility magnetic resonance imaging at initial tumor diagnosis with the prognosis of different molecular glioma subtypes.
Neoplasms
Association of Isocitrate Dehydrogenase (IDH) Status With Edema to Tumor Ratio and Its Correlation With Immune Infiltration in Glioblastoma.
Neoplasms
Association of preoperative seizures with tumor metabolites quantified by magnetic resonance spectroscopy in gliomas.
Neoplasms
BCAT1 is a New MR Imaging-related Biomarker for Prognosis Prediction in IDH1-wildtype Glioblastoma Patients.
Neoplasms
Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study.
Neoplasms
Beyond the Influence of IDH Mutations: Exploring Epigenetic Vulnerabilities in Chondrosarcoma.
Neoplasms
Biochemical changes in endometrial carcinoma and their correlation to clinical outcome and prognosis.
Neoplasms
Biochemical markers of central nervous system tumors measured in cerebrospinal fluid and their potential use in diagnosis and patient management: a review.
Neoplasms
Brain Tumor-Related Epilepsy: a Current Review of the Etiologic Basis and Diagnostic and Treatment Approaches.
Neoplasms
Breaking the ritual metabolic cycle in order to save acetyl CoA: A potential role for mitochondrial humanin in T2 bladder cancer aggressiveness.
Neoplasms
Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation.
Neoplasms
Cancer and Altered Metabolism: Potential Importance of Hypoxia-Inducible Factor and 2-Oxoglutarate-Dependent Dioxygenases.
Neoplasms
Cancer-associated 2-oxoglutarate analogues modify histone methylation by inhibiting histone lysine demethylases.
Neoplasms
Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition.
Neoplasms
Cancer-associated isocitrate dehydrogenase mutations induce mitochondrial DNA instability.
Neoplasms
CARD-Associated Risk Score Features the Immune Landscape and Predicts the Responsiveness to Anti-PD-1 Therapy in IDH Wild-Type Gliomas.
Neoplasms
CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Neoplasms
Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma.
Neoplasms
Characterisation of isocitrate dehydrogenase gene mutant WHO grade 2 and 3 gliomas: MRI predictors of 1p/19q co-deletion and tumour grade.
Neoplasms
Characterization of systemic immunosuppression by IDH mutant glioma small extracellular vesicles.
Neoplasms
Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial.
Neoplasms
Choroid Plexus as the Best Reference Region for Standardized Uptake Value Analysis on C11-Acetate PET/CT for Grading and Predicting Prognosis in Patients with Cerebral Gliomas.
Neoplasms
Chromatographic methods coupled to mass spectrometry for the determination of oncometabolites in biological samples-A review.
Neoplasms
Chronic nickel (II) exposure induces the stemness properties of cancer cells through repressing isocitrate dehydrogenase (IDH1).
Neoplasms
CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Neoplasms
Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms.
Neoplasms
Clinical and histological characteristics of recurrent oligodendroglial tumors: comparison between primary and recurrent tumors in 18 cases.
Neoplasms
Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation.
Neoplasms
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.
Neoplasms
Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors.
Neoplasms
COL4A1 as a novel oncogene associated with the clinical characteristics of malignancy predicts poor prognosis in glioma.
Neoplasms
Combination of diffusion tensor imaging and conventional MRI correlates with isocitrate dehydrogenase 1/2 mutations but not 1p/19q genotyping in oligodendroglial tumours.
Neoplasms
Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms.
Neoplasms
Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature.
Neoplasms
Computer-aided diagnosis of isocitrate dehydrogenase genotypes in glioblastomas from radiomic patterns.
Neoplasms
Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens.
Neoplasms
Correlation Between Tumor Location and Clinical Properties of Glioblastomas in Frontal and Temporal Lobes.
Neoplasms
Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.
Neoplasms
D-2-Hydroxyglutarate and L-2-Hydroxyglutarate Inhibit IL-12 Secretion by Human Monocyte-Derived Dendritic Cells.
Neoplasms
Dabrafenib Treatment in a Patient with an Epithelioid Glioblastoma and BRAF V600E Mutation.
Neoplasms
Deletions on Chromosome Y and Downregulation of the SRY Gene in Tumor Tissue Are Associated with Worse Survival of Glioblastoma Patients.
Neoplasms
Detecting isocitrate dehydrogenase gene mutations in oligodendroglial tumors using diffusion tensor imaging metrics and their correlations with proliferation and microvascular density.
Neoplasms
Detection of "oncometabolite" 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma.
Neoplasms
Detection of IDH1 and IDH2 Mutation in Formalin-fixed Paraffin-embedded Gliomas Using Allele-specific COLD-PCR and Probe Melting Curve Analysis.
Neoplasms
Detection of Isocitrate Dehydrogenase Mutated Glioblastomas Through Anomaly Detection Analytics.
Neoplasms
Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate.
Neoplasms
Development of a Microfluidic Culture Paradigm for Ex Vivo Maintenance of Human Glioblastoma Tissue: A New Glioblastoma Model?
Neoplasms
Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer.
Neoplasms
Differential Predictors and Clinical Implications Associated With Long-Term Survivors in IDH Wildtype and Mutant Glioblastoma.
Neoplasms
Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
Neoplasms
Distinct TERT promoter C228T and C250T mutations in a patient with an oligodendroglioma: A case report.
Neoplasms
Diversity in cell differentiation, histology, phenotype and vasculature of mass-forming intrahepatic cholangiocarcinomas.
Neoplasms
DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.
Neoplasms
DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival.
Neoplasms
DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development.
Neoplasms
Droplet digital PCR assay for detecting TERT promoter mutations in patients with glioma.
Neoplasms
Dual-layer detector spectral CT-a new supplementary method for preoperative evaluation of glioma.
Neoplasms
Echo-planar spectroscopic imaging with dual-readout alternated gradients (DRAG-EPSI) at 7 T: Application for 2-hydroxyglutarate imaging in glioma patients.
Neoplasms
Effect of IDH3a on glucose uptake in lung adenocarcinoma: A pilot study based on [18 F]FDG.
Neoplasms
Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma.
Neoplasms
Effective use of small-interfering RNA to characterize residual B-cell non-Hodgkin lymphoma cells following chemotherapy.
Neoplasms
Effectiveness of Stereotactic Radiotherapy and Bevacizumab for Recurrent High-grade gliomas -A Potential Therapy for IDH Wild-type Recurrent High-grade Gliomas.
Neoplasms
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
Neoplasms
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.
Neoplasms
Enzyme activities of six different dehydrogenases in Ehrlich ascites cells measured by flow cytometry.
Neoplasms
Enzymes in cancer. 2. The isocitric dehydrogenase of the cerebrospinal fluid in various cancerous and noncancerous conditions.
Neoplasms
Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.
Neoplasms
Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations.
Neoplasms
Evidence that 2-hydroxyglutarate is not readily metabolized in colorectal carcinoma cells.
Neoplasms
Evolutionary Trajectories of IDHWT Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis.
Neoplasms
Expression profiling of the adhesion G protein-coupled receptor GPR133 (ADGRD1) in glioma subtypes.
Neoplasms
Fatty acid labeling from glutamine in hypoxia can be explained by isotope exchange without net reductive IDH flux.
Neoplasms
Fisetin modulates mitochondrial enzymes and apoptotic signals in benzo(a)pyrene-induced lung cancer.
Neoplasms
Flow-cytometric determination of dehydrogenase activities in primary human gastrointestinal tumor cell lines.
Neoplasms
Fluid attenuation in non-contrast-enhancing tumor (nCET): an MRI Marker for Isocitrate Dehydrogenase (IDH) mutation in Glioblastoma.
Neoplasms
Frequent Diagnostic Under-Grading in Isocitrate Dehydrogenase Wild-Type Gliomas due to Small Pathological Tissue Samples.
Neoplasms
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
Neoplasms
GC/MS-based metabolomic analysis of cerebrospinal fluid (CSF) from glioma patients.
Neoplasms
Generation of a novel monoclonal antibody WMab-1 specific for IDH2-R172W mutation.
Neoplasms
Genetic and epigenetic alterations in primary-progressive paired oligodendroglial tumors.
Neoplasms
Genetic dissection of leukemia-associated IDH1 and IDH2 mutants and D-2-hydroxyglutarate in Drosophila.
Neoplasms
Genome wide DNA copy number analysis in cholangiocarcinoma using high resolution molecular inversion probe single nucleotide polymorphism assay.
Neoplasms
Genomic profiling of lower-grade gliomas uncovers cohesive disease groups: implications for diagnosis and treatment.
Neoplasms
Glioblastoma Cellular Origin and the Firework Pattern of Cancer Genesis from the Subventricular Zone.
Neoplasms
Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome.
Neoplasms
Glioma grading, molecular feature classification, and microstructural characterization using MR diffusional variance decomposition (DIVIDE) imaging.
Neoplasms
Glioneuronal tumours with features of rosette-forming glioneuronal tumours of the fourth ventricle and dysembryoplastic neuroepithelial tumours: a report of three cases.
Neoplasms
GNG5 is a novel oncogene associated with cell migration, proliferation, and poor prognosis in glioma.
Neoplasms
Grading of Diffuse Astrocytic Gliomas: A Review of Studies Before and After the Advent of IDH Testing.
Neoplasms
Heterogeneity of tumor-induced gene expression changes in the human metabolic network.
Neoplasms
Heterogeneous parameters based on 18F-FET PET imaging can non-invasively predict tumor grade and isocitrate dehydrogenase gene 1 mutation in untreated gliomas.
Neoplasms
High expression of 5-hydroxymethylcytosine and isocitrate dehydrogenase 2 is associated with favorable prognosis after curative resection of hepatocellular carcinoma.
Neoplasms
High-Resolution Cartography of the Transcriptome and Methylome Landscapes of Diffuse Gliomas.
Neoplasms
HISTOCHEMICAL STUDIES ON THE LOCALIZATION OF ISOCITRIC DEHYDROGENASE IN HUMAN TUMORS.
Neoplasms
Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas.
Neoplasms
Huge heterogeneity in survival in a subset of adult patients with resected, wild-type isocitrate dehydrogenase status, WHO grade II astrocytomas.
Neoplasms
Human glioblastoma arises from subventricular zone cells with low-level driver mutations.
Neoplasms
Human Phosphoglycerate Dehydrogenase Produces the Oncometabolite d-2-Hydroxyglutarate.
Neoplasms
Hypoxia-associated factor expression in low-grade and anaplastic gliomas: a marker of poor outcome.
Neoplasms
Identification of IDH and TERTp mutation status using 1 H-MRS in 112 hemispheric diffuse gliomas.
Neoplasms
Identification of integrative molecular and clinical profiles of Fibrinogen-like protein 2 in gliomas using 1323 samples.
Neoplasms
Identification of two core genes in glioblastomas with different isocitrate dehydrogenase mutation status.
Neoplasms
IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations.
Neoplasms
IDH Mutation Detection in Formalin-Fixed Paraffin-Embedded Gliomas Using Multiplex PCR and Single-base Extension.
Neoplasms
IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas.
Neoplasms
IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients.
Neoplasms
IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas.
Neoplasms
IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F.
Neoplasms
IDH-Mutant Brain Tumors Hit the Achilles' Heel of Macrophages with R-2-Hydroxyglutarate.
Neoplasms
IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms.
Neoplasms
IDH1 Expression via the R132H Mutation-Specific Antibody in Adrenocortical Neoplasias-Prognostic Impact in Carcinomas.
Neoplasms
IDH1 Mutation Is an Independent Inferior Prognostic Indicator for Patients with Myelodysplastic Syndromes.
Neoplasms
IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity.
Neoplasms
IDH1/IDH2 but not TP53 mutations predict prognosis in Bulgarian glioblastoma patients.
Neoplasms
IDH2 compensates for IDH1 mutation to maintain cell survival under hypoxic conditions in IDH1?mutant tumor cells.
Neoplasms
IDH2 reprograms mitochondrial dynamics in cancer through a HIF-1?-regulated pseudohypoxic state.
Neoplasms
Immune Profiling of Gliomas Reveals a Connection with IDH1/2 Mutations, Tau Function and the Vascular Phenotype.
Neoplasms
Immunohistochemical and molecular genetics study of a granular cell astrocytoma: A case report of malignant transformation to a glioblastoma.
Neoplasms
Impact of epidemiological characteristics of supratentorial gliomas in adults brought about by the 2016 world health organization classification of tumors of the central nervous system.
Neoplasms
Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm.
Neoplasms
Influence of HSP27 and steroid receptor status on provera sensitivity, DNA-ploidy and survival of females with endometrial cancer.
Neoplasms
Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management.
Neoplasms
Inhibition of Glycolysis and Glutaminolysis: An Emerging Drug Discovery Approach to Combat Cancer.
Neoplasms
Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities.
Neoplasms
Integrative transcriptome analysis identified a BMP signaling pathway-regulated lncRNA AC068643.1 in IDH mutant and wild-type glioblastomas.
Neoplasms
Intraoperative assessment of tumor margins during glioma resection by desorption electrospray ionization-mass spectrometry.
Neoplasms
Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery.
Neoplasms
Intraoperative Mass Spectrometry Platform for IDH Mutation Status Prediction, Glioma Diagnosis, and Estimation of Tumor Cell Infiltration.
Neoplasms
In Vivo Imaging of Glutamine Metabolism to the Oncometabolite 2-Hydroxyglutarate in IDH1/2 Mutant Tumors.
Neoplasms
Is chemotherapy alone an option as initial treatment for low-grade oligodendrogliomas?
Neoplasms
Isocitrate Dehydrogenase (IDH) Inhibition as Treatment of Myeloid Malignancies: Progress and Future Directions.
Neoplasms
Isocitrate dehydrogenase (IDH) status prediction in histopathology images of gliomas using deep learning.
Neoplasms
Isocitrate dehydrogenase (IDH), succinate dehydrogenase (SDH), fumarate hydratase (FH): three players for one phenotype in cancer?
Neoplasms
Isocitrate dehydrogenase (IDH)2 R140Q mutation induces myeloid and lymphoid neoplasms in mice.
Neoplasms
Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
Neoplasms
Isocitrate dehydrogenase 1 mutation enhances 24(S)-hydroxycholesterol production and alters cholesterol homeostasis in glioma.
Neoplasms
Isocitrate dehydrogenase 1-mutated cancers are sensitive to the green tea polyphenol epigallocatechin-3-gallate.
Neoplasms
Isocitrate dehydrogenase 1/2 mutational analyses and 2-hydroxyglutarate measurements in Wilms tumors.
Neoplasms
Isocitrate Dehydrogenase 2 Inhibitors for the Treatment of Hematologic Malignancies: Advances and Future Opportunities.
Neoplasms
Isocitrate dehydrogenase 2 inhibits gastric cancer cell invasion via matrix metalloproteinase 7.
Neoplasms
Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1.
Neoplasms
Isocitrate Dehydrogenase 2 Suppresses the Invasion of Hepatocellular Carcinoma Cells via Matrix Metalloproteinase 9.
Neoplasms
Isocitrate dehydrogenase 3A, a rate-limiting enzyme of the TCA cycle, promotes hepatocellular carcinoma migration and invasion through regulation of MTA1, a core component of the NuRD complex.
Neoplasms
Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.
Neoplasms
Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms.
Neoplasms
Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone.
Neoplasms
Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.
Neoplasms
Isocitrate dehydrogenase mutations in defining the biology of and supporting clinical decision making in glioblastoma.
Neoplasms
Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications.
Neoplasms
Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients.
Neoplasms
Isocitrate dehydrogenase variants in cancer - Cellular consequences and therapeutic opportunities.
Neoplasms
Isocitrate dehydrogenase1 mutation reduces the pericyte coverage of microvessels in astrocytic tumours.
Neoplasms
JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition.
Neoplasms
L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer.
Neoplasms
Lower Lactate Levels and Lower Intracellular pH in Patients with IDH-Mutant versus Wild-Type Gliomas.
Neoplasms
Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells.
Neoplasms
Management of diffuse low-grade gliomas in adults - use of molecular diagnostics.
Neoplasms
Metabolic modulation of cancer: a new frontier with great translational potential.
Neoplasms
Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma.
Neoplasms
Mismatch repair proteins PMS2 and MLH1 can further refine molecular stratification of IDH-mutant lower grade astrocytomas.
Neoplasms
Mitochondrial dysfunctions in cancer: Genetic defects and oncogenic signaling impinging on TCA cycle activity.
Neoplasms
Molecular and clinical characterization of CD163 expression via large-scale analysis in glioma.
Neoplasms
Molecular classification defines 4 prognostically distinct glioma groups irrespective of diagnosis and grade.
Neoplasms
Molecular diagnostics of gliomas using next generation sequencing of a glioma-tailored gene panel.
Neoplasms
Molecular modeling studies to discover novel mIDH2 inhibitors with high selectivity for the primary and secondary mutants.
Neoplasms
Molecular Pathways: Mitochondrial Reprogramming in Tumor Progression and Therapy.
Neoplasms
Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma.
Neoplasms
MR image phenotypes may add prognostic value to clinical features in IDH wild-type lower-grade gliomas.
Neoplasms
MRI Atlas of IDH Wild-Type Supratentorial Glioblastoma: Probabilistic Maps of Phenotype, Management, and Outcomes.
Neoplasms
MRI-Based Radiomics and Radiogenomics in the Management of Low-Grade Gliomas: Evaluating the Evidence for a Paradigm Shift.
Neoplasms
Multi-specific monoclonal antibody MsMab-2 recognizes IDH1-R132L and IDH2-R172M mutations.
Neoplasms
Multiparametric and multiregional diffusion features help predict molecule information, grade and survival in lower-grade gliomas: a feasibility study.
Neoplasms
Multiparametric MR Imaging of Diffusion and Perfusion in Contrast-enhancing and Nonenhancing Components in Patients with Glioblastoma.
Neoplasms
Mutant IDH1 confers resistance to energy stress in normal biliary cells through PFKP-induced aerobic glycolysis and AMPK activation.
Neoplasms
Mutant IDH1 cooperates with ATRX loss to drive the alternative lengthening of telomere (ALT) phenotype in glioma.
Neoplasms
Mutation of IDH1 aggravates the fatty acid?induced oxidative stress in HCT116 cells by affecting the mitochondrial respiratory chain.
Neoplasms
Myoinositol to Total Choline Ratio in Glioblastomas as a Potential Prognostic Factor in Preoperative Magnetic Resonance Spectroscopy.
Neoplasms
Non-enzymatic chemistry enables 2-hydroxyglutarate-mediated activation of 2-oxoglutarate oxygenases.
Neoplasms
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations.
Neoplasms
Non-measurable speckled contrast-enhancing lesions appearing during course of disease are associated with IDH mutation in high-grade astrocytoma patients.
Neoplasms
Overexpression of MTH1 and OGG1 proteins in ulcerative colitis-associated carcinogenesis.
Neoplasms
Papillary tumor of the pineal region: a case involving isocitrate dehydrogenase (IDH) genotyping.
Neoplasms
Partial resection offers an overall survival benefit over biopsy in MGMT-unmethylated IDH-wildtype glioblastoma patients.
Neoplasms
PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations.
Neoplasms
Pediatric glioblastoma with oligodendroglioma component: Aggressive clinical phenotype with distinct molecular characteristics.
Neoplasms
Perfusion Parameter Obtained on 3-Tesla Magnetic Resonance Imaging and the Ki-67 Labeling Index Predict the Overall Survival of Glioblastoma.
Neoplasms
Pharmacological characterization of TQ05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants.
Neoplasms
Pharmacotranscriptomic Analysis Reveals Novel Drugs and Gene Networks Regulating Ferroptosis in Cancer.
Neoplasms
Photoactivation of Mutant Isocitrate Dehydrogenase 2 Reveals Rapid Cancer-Associated Metabolic and Epigenetic Changes.
Neoplasms
Plasma and cerebrospinal fluid pharmacokinetics of the DNA methyltransferase inhibitor, 5-azacytidine, alone and with inulin, in nonhuman primate models.
Neoplasms
Potential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancers.
Neoplasms
Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[18F]-fluoroethyl)-L-tyrosine PET.
Neoplasms
Preoperative Changes in Hematological Markers and Predictors of Glioma Grade and Survival.
Neoplasms
Preoperative imaging of glioblastoma patients using hyperpolarized 13C pyruvate: Potential role in clinical decision making.
Neoplasms
Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.
Neoplasms
Prognostic implications of epidermal growth factor receptor variant III expression and nuclear translocation in Chinese human gliomas.
Neoplasms
Prognostic Importance of Age, Tumor Location, and Tumor Grade in Grade II Astrocytomas: An Integrated Analysis of the Cancer Genome Atlas and the Surveillance, Epidemiology, and End Results Database.
Neoplasms
Prognostic Value of Preoperative MRI Metrics for Diffuse Lower-Grade Glioma Molecular Subtypes.
Neoplasms
Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma.
Neoplasms
Proteomic profiling of differential display analysis for human oral squamous cell carcinoma: 14-3-3 ? Protein is upregulated in human oral squamous cell carcinoma and dependent on the differentiation level.
Neoplasms
Quantification of 2-Hydroxyglutarate Enantiomers by Liquid Chromatography-mass Spectrometry.
Neoplasms
Quantitation of isocitrate dehydrogenase (IDH)-induced D and L enantiomers of 2-hydroxyglutaric acid in biological fluids by a fully validated liquid tandem mass spectrometry method, suitable for clinical applications.
Neoplasms
Radiological and pathological features associated with IDH1-R132H mutation status and early mortality in newly diagnosed anaplastic astrocytic tumours.
Neoplasms
Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells.
Neoplasms
Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry.
Neoplasms
Rapid determination of isocitrate dehydrogenase mutation status of human gliomas by extraction nanoelectrospray using a miniature mass spectrometer.
Neoplasms
Recent Advances in Targeted Therapies for Advanced Gastrointestinal Malignancies.
Neoplasms
Recent Developments and Future Directions in Adult Lower-Grade Gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) Consensus.
Neoplasms
Receptor tyrosine kinase expression in high-grade gliomas before and after chemoradiotherapy.
Neoplasms
Regional and Volumetric Parameters for Diffusion-Weighted WHO Grade II and III Glioma Genotyping: A Method Comparison.
Neoplasms
Relationship of Molecular Genetic Tumor Marker IDH with Oxidative Status in Gliomas.
Neoplasms
Reprogramming of Isocitrate Dehydrogenases Expression and Activity by the Androgen Receptor in Prostate Cancer.
Neoplasms
Revisiting vimentin: a negative surrogate marker of molecularly defined oligodendroglioma in adult type diffuse glioma.
Neoplasms
Risks and Benefits of Glioblastoma Resection in Older Adults: A Retrospective Austrian Multicenter Study.
Neoplasms
Sclerosing stromal tumor of the ovary. A light, electron microscopic and enzyme histochemical study.
Neoplasms
Sequential implementation of DSC-MR perfusion and dynamic [18F]FET PET allows efficient differentiation of glioma progression from treatment-related changes.
Neoplasms
Single arginine mutation in two yeast isocitrate dehydrogenases: biochemical characterization and functional implication.
Neoplasms
Solitary primary intracranial leptomeningeal glioblastoma invading the normal cortex: Case report.
Neoplasms
Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
Neoplasms
Spinal Cord Diffuse Midline Gliomas With H3 K27m-Mutant: Clinicopathological Features and Prognosis.
Neoplasms
Steroids from Ganoderma sinense as new natural inhibitors of cancer-associated mutant IDH1.
Neoplasms
Structure-based design, synthesis and bioactivity evaluation of macrocyclic inhibitors of mutant isocitrate dehydrogenase 2 (IDH2) displaying activity in acute myeloid leukemia cells.
Neoplasms
Studies on the Interaction of the Histone Demethylase KDM5B with Tricarboxylic Acid Cycle Intermediates.
Neoplasms
Studies on the isocitrate dehydrogenase. II. Isocitrate dehydrogenase and transhydrogenase in tumor bearing rat liver and ascites tumor cells.
Neoplasms
Super-Resolution Whole-Brain 3D MR Spectroscopic Imaging for Mapping D-2-Hydroxyglutarate and Tumor Metabolism in Isocitrate Dehydrogenase 1-mutated Human Gliomas.
Neoplasms
Survival benefit of lobectomy over gross-total resection without lobectomy in cases of glioblastoma in the noneloquent area: a retrospective study.
Neoplasms
T2 mapping of the peritumoral infiltration zone of glioblastoma and anaplastic astrocytoma.
Neoplasms
Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.
Neoplasms
Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
Neoplasms
Targeting isocitrate dehydrogenase mutations in cancer: emerging evidence and diverging strategies.
Neoplasms
Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas.
Neoplasms
Telomerase reverse transcriptase promoter mutation- and O6-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?
Neoplasms
Ten-Eleven Translocation-2 gene mutations: A potential new molecular marker in malignant gliomas (Review).
Neoplasms
TERT Promoter Mutation Detection in Cell-Free Tumor-Derived DNA in Patients with IDH Wild-Type Glioblastomas: A Pilot Prospective Study.
Neoplasms
The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas.
Neoplasms
The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision.
Neoplasms
The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.
Neoplasms
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Neoplasms
The effectiveness of salvage treatments for recurrent lesions of oligodendrogliomas previously treated with upfront chemotherapy.
Neoplasms
The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development.
Neoplasms
The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
Neoplasms
The long non-coding RNA Cancer Susceptibility 15 is induced by Isocitrate Dehydrogenase mutations and maintains an immature phenotype in adult acute myeloid leukemia.
Neoplasms
The oncometabolite R-2-hydroxyglutarate dysregulates the differentiation of human mesenchymal stromal cells via inducing DNA hypermethylation.
Neoplasms
The prognostic impact of ventricular opening in glioblastoma surgery: a retrospective single center analysis.
Neoplasms
The Relationship Between Stimulation Current and Functional Site Localization During Brain Mapping.
Neoplasms
The role of deep learning-based survival model in improving survival prediction of patients with glioblastoma.
Neoplasms
The role of metabolic enzymes in mesenchymal tumors and tumor syndromes: genetics, pathology, and molecular mechanisms.
Neoplasms
The studies on glycolytic enzymes in relation to cancer. II. Comparative study of phosphohexose-isomerase, aldolase, isocitric dehydrogenase, serum glutamic oxaloacetic and pyruvic transaminase, and alkaline phosphatase in liver.
Neoplasms
Therapeutic effect of tamoxifen and energy-modulating vitamins on carbohydrate-metabolizing enzymes in breast cancer.
Neoplasms
Transcriptional alterations in glioma result primarily from DNA methylation-independent mechanisms.
Neoplasms
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.
Neoplasms
Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
Neoplasms
Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism.
Neoplasms
Tumor-related neurocognitive dysfunction in patients with diffuse glioma: a retrospective cohort study prior to antitumor treatment.
Neoplasms
Ultra-high-field sodium MRI as biomarker for tumor extent, grade and IDH mutation status in glioma patients.
Neoplasms
Usefulness of positron emission tomography for differentiating gliomas according to the 2016 World Health Organization classification of tumors of the central nervous system.
Neoplasms
Validation of a routine gas chromatography mass spectrometry method for 2-hydroxyglutarate quantification in human serum as a screening tool for detection of idh mutations.
Neoplasms
Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma.
Neoplasms
Voxel-wise radiogenomic mapping of tumor location with key molecular alterations in patients with glioma.
Neoplasms
Who controls the ATP supply in cancer cells? Biochemistry lessons to understand cancer energy metabolism.
Neoplasms
Widespread overexpression from the four DNA hypermethylated HOX clusters in aggressive (IDHwt) glioma is associated with H3K27me3 depletion and alternative promoter usage.
Neoplasms
Wild-type IDH2 protects nuclear DNA from oxidative damage and is a potential therapeutic target in colorectal cancer.
Neoplasms
Withanolides from dietary tomatillo suppress HT1080 cancer cell growth by targeting mutant IDH1.
Neoplasms
World Health Organization grade II-III astrocytomas consist of genetically distinct tumor lineages.
Neoplasms
World Health Organization Grade II/III Glioma Molecular Status: Prediction by MRI Morphologic Features and Apparent Diffusion Coefficient.
Neoplasms
Worse prognosis for IDH wild-type diffuse gliomas with larger residual biological tumor burden.
Neoplasms
[IDH mutations activate Hoxa9/Meis1 and hypoxia pathways in acute myeloid leukemia model mice].
Neoplasms
[Isomerase phosphohexose, isocitric dehydrogenase, and alkaline phosphatase in cancer patients]
Neoplasms
[Studies on the recording of cytostatic effects on organ cultures of squamous cell carcinoma of the uterine cervix]
Neoplasms
[Value of Serum Tumor Marker Isocitrate Dehydrogenase 1 in the Diagnosis of Lung Cancer].
Nephrotic Syndrome
Activity of serum enzymes in puromycin aminonucleoside-induced nephrotic syndrome.
Nervous System Diseases
Isocitric dehydrogenase activity of the cerebrospinal fluid of children with neurologic disorders.
Neuroblastoma
Mitochondrial isocitrate dehydrogenase protects human neuroblastoma SH-SY5Y cells against oxidative stress.
Non-alcoholic Fatty Liver Disease
IDH2 Deficiency Aggravates Fructose-Induced NAFLD by Modulating Hepatic Fatty Acid Metabolism and Activating Inflammatory Signaling in Female Mice.
Obesity
Increased obesity resistance and insulin sensitivity in mice lacking the isocitrate dehydrogenase 2 gene.
Oligodendroglioma
Association of dynamic susceptibility magnetic resonance imaging at initial tumor diagnosis with the prognosis of different molecular glioma subtypes.
Oligodendroglioma
Clinical implications of molecular analysis in diffuse glioma stratification.
Oligodendroglioma
Clinical significance of the 2016 WHO classification in Japanese patients with gliomas.
Oligodendroglioma
Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature.
Oligodendroglioma
Detection of 2-Hydroxyglutarate in Formalin-Fixed Paraffin-Embedded Glioma Specimens by Gas Chromatography/Mass Spectrometry.
Oligodendroglioma
Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues.
Oligodendroglioma
Diagnostic Utility of Oncomine Comprehensive Assay v3 in Differentiating Between Isocitrate Dehydrogenase (IDH)-mutated Grade II-III Astrocytoma and Oligodendroglioma.
Oligodendroglioma
DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Oligodendroglioma
Elevated TERT Expression in TERT-Wildtype Adult Diffuse Gliomas: Histological Evaluation with a Novel TERT-Specific Antibody.
Oligodendroglioma
Elucidation of the TMab-6 Monoclonal Antibody Epitope Against Telomerase Reverse Transcriptase.
Oligodendroglioma
Gliosarcoma arising from oligodendroglioma, IDH mutant and 1p/19q codeleted.
Oligodendroglioma
Highly sensitive detection of TERT promoter mutations in recurrent glioblastomas using digital PCR.
Oligodendroglioma
Histone 3 Lysine 9 Trimethylation Is Differentially Associated With Isocitrate Dehydrogenase Mutations in Oligodendrogliomas and High-Grade Astrocytomas.
Oligodendroglioma
IDH mutant and 1p/19q co-deleted oligodendrogliomas: tumor grade stratification using diffusion-, susceptibility-, and perfusion-weighted MRI.
Oligodendroglioma
IDH mutations associated impact on related cancer epidemiology and subsequent effect toward HIF-1?.
Oligodendroglioma
Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management.
Oligodendroglioma
Is chemotherapy alone an option as initial treatment for low-grade oligodendrogliomas?
Oligodendroglioma
Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas.
Oligodendroglioma
Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study.
Oligodendroglioma
Magnetic resonance imaging criteria for prediction of isocitrate dehydrogenase (IDH) mutation status in patients with grade II-III astrocytoma and oligodendroglioma.
Oligodendroglioma
Management of diffuse low-grade gliomas in adults - use of molecular diagnostics.
Oligodendroglioma
Molecular subclassification of diffuse gliomas: Seeing order in the chaos.
Oligodendroglioma
Mutant IDH sensitizes gliomas to endoplasmic reticulum stress and triggers apoptosis by MicroRNA183-mediated inhibition of Semaphorin 3E.
Oligodendroglioma
Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity.
Oligodendroglioma
Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in IDH-Mutant Lower Grade Gliomas.
Oligodendroglioma
Pattern of failure in anaplastic glioma patients with an IDH1/2 mutation.
Oligodendroglioma
Reproducible imaging-based prediction of molecular subtype and risk stratification of gliomas across different experience levels using a structured reporting system.
Oligodendroglioma
Somatostatin receptor 2A in gliomas: Association with oligodendrogliomas and favourable outcome.
Oligodendroglioma
Survival, Prognostic Factors, and Volumetric Analysis of Extent of Resection for Anaplastic Gliomas.
Oligodendroglioma
Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.
Oligodendroglioma
Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.
Oligodendroglioma
Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
Oligodendroglioma
Widely metastatic IDH1-mutant glioblastoma with oligodendroglial features and atypical molecular findings: a case report and review of current challenges in molecular diagnostics.
Osteosarcoma
A novel monoclonal antibody SMab-2 recognizes endogenous IDH2-R172S of chondrosarcoma.
Osteosarcoma
Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1.
Osteosarcoma
Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone.
Osteosarcoma
Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
Pancreatic Neoplasms
Flow-cytometric determination of dehydrogenase activities in primary human gastrointestinal tumor cell lines.
Pancreatic Neoplasms
Recent Advances in Targeted Therapies for Advanced Gastrointestinal Malignancies.
Paraganglioma
Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas.
Paraganglioma
Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma.
Paraproteinemias
IDH2 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in multiple myeloma.
Peptic Ulcer
Isocitrate Dehydrogenase of Helicobacter pylori Potentially Induces Humoral Immune Response in Subjects with Peptic Ulcer Disease and Gastritis.
Periodontitis
Expression of TET2 enzyme indicates enhanced epigenetic modification of cells in periodontitis.
Pheochromocytoma
Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas.
Pheochromocytoma
Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Isocitrate dehydrogenase mutation hot spots in acute lymphoblastic leukemia and oral cancer.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Mutation analysis of isocitrate dehydrogenase in acute lymphoblastic leukemia.
Prostatic Hyperplasia
Isocitrate dehydrogenase activity in untreated and treated benign prostatic hypertrophy and adenocarcinomatous prostate.
Prostatic Neoplasms
Modulation of hypoxia-inducible factor-1? expression by mitochondrial NADP(+)-dependent isocitrate dehydrogenase.
Prostatic Neoplasms
Reprogramming of Isocitrate Dehydrogenases Expression and Activity by the Androgen Receptor in Prostate Cancer.
Prostatic Neoplasms
Synthesis and Comparative In Vivo Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPET.
Psoriasis
Epidermal activity of NAD-dependent isocitrate dehydrogenase in psoriasis during treatment with dithranol.
Psoriasis
Isozymes of NADP-linked isocitric dehydrogenase in psoriasis and human basal cell carcinoma.
Pyelonephritis
[Serum and urine isocitrate dehydrogenase activity in patients with chronic pyelonephritis]
Reperfusion Injury
Mitochondrial NADP(+)-Dependent Isocitrate Dehydrogenase Deficiency Exacerbates Mitochondrial and Cell Damage after Kidney Ischemia-Reperfusion Injury.
Retinal Degeneration
A novel missense variant in IDH3A causes autosomal recessive retinitis pigmentosa.
Retinal Degeneration
Mouse Idh3a mutations cause retinal degeneration and reduced mitochondrial function.
Retinitis Pigmentosa
A novel missense variant in IDH3A causes autosomal recessive retinitis pigmentosa.
Retinitis Pigmentosa
Whole-Exome Sequencing Identifies Biallelic IDH3A Variants as a Cause of Retinitis Pigmentosa Accompanied by Pseudocoloboma.
Sarcoma
Steroids from Ganoderma sinense as new natural inhibitors of cancer-associated mutant IDH1.
Sarcoma
Targets for therapy in biliary tract cancers: the new horizon of personalized medicine.
Sarcoma
The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
Schistosomiasis
Serum isocitric dehydrogenase and glutamic dehydrogenase in schistosomiasis.
Seizures
Association of preoperative seizures with tumor metabolites quantified by magnetic resonance spectroscopy in gliomas.
Seizures
Brain Tumor-Related Epilepsy: a Current Review of the Etiologic Basis and Diagnostic and Treatment Approaches.
Seizures
IDH mutations but not TERTp mutations are associated with seizures in lower-grade gliomas.
Seizures
IDH1/2 mutation is associated with seizure as an initial symptom in low-grade glioma: A report of 311 Chinese adult glioma patients.
Seizures
Isocitrate dehydrogenase mutations: A biomarker for glioma-related excitability and seizures.
Seminoma
Modified expression of cytoplasmic isocitrate dehydrogenase electrophoretic isoforms in seminal plasma of men with sertoli-cell-only syndrome and seminoma.
Small Cell Lung Carcinoma
Pharmacotranscriptomic Analysis Reveals Novel Drugs and Gene Networks Regulating Ferroptosis in Cancer.
Small Cell Lung Carcinoma
Synthesis and Comparative In Vivo Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPET.
Starvation
Biochemical characterization of NADP(+)-dependent isocitrate dehydrogenase from Microcystis aeruginosa PCC7806.
Starvation
Metabolic and ultrastructural responses of lupine embryo axes to sugar starvation.
Starvation
Physiological regulation of isocitrate dehydrogenase and the role of 2-oxoglutarate in Prochlorococcus sp. strain PCC 9511.
Stomach Neoplasms
Flow-cytometric determination of dehydrogenase activities in primary human gastrointestinal tumor cell lines.
Stomach Neoplasms
Isocitrate Dehydrogenase 2 Dysfunction Contributes to 5-hydroxymethylcytosine Depletion in Gastric Cancer Cells.
Stomach Neoplasms
Isocitrate dehydrogenase 2 inhibits gastric cancer cell invasion via matrix metalloproteinase 7.
Stomach Neoplasms
Robust quantitative assessments of cytosine modifications and changes in the expressions of related enzymes in gastric cancer.
Tauopathies
Identification of non-Alzheimer's disease tauopathies-related proteins by proteomic analysis.
Thyroid Cancer, Papillary
Functional analysis and clinical significance of the isocitrate dehydrogenase 2 gene in papillary thyroid carcinoma.
Thyroid Neoplasms
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.
Triple Negative Breast Neoplasms
Serine biosynthesis is a metabolic vulnerability in IDH2-driven breast cancer progression.
Tuberculosis
Cloning, expression, purification, crystallization and preliminary X-ray crystallographic analysis of isocitrate dehydrogenase 2 (Rv0066c) from Mycobacterium tuberculosis.
Tuberculosis
Comparison of Mycobacterium tuberculosis isocitrate dehydrogenases (ICD-1 and ICD-2) reveals differences in coenzyme affinity, oligomeric state, pH tolerance and phylogenetic affiliation.
Tuberculosis
Development of mycobacterial species-specific DNA probes by subtraction hybridization.
Tuberculosis
Further studies with isocitric dehydrogenase in experimental tuberculosis: influence of isoniazid on metabolic damage.
Tuberculosis
Identification, molecular cloning, and evaluation of potential use of isocitrate dehydrogenase II of Mycobacterium bovis BCG in serodiagnosis of tuberculosis.
Tuberculosis
Isocitric dehydrogenase and nicotinamide adenine dinucleotidase in experimental tuberculosis: influence of isoniazid on metabolic damage.
Tuberculosis
Purification and characterisation of isocitrate dehydrogenase and malate dehydrogenase from Mycobacterium tuberculosis and evaluation of their potential as suitable antigens for the serodiagnosis of tuberculosis.
Urinary Bladder Neoplasms
Identification of differentially expressed proteins during human urinary bladder cancer progression.
Uterine Hemorrhage
Piperazine oestrone sulphate and interrupted norethisterone: effects on the postmenopausal endometrium.
Venous Thromboembolism
Association between IDH mutational status and tumor-associated epilepsy or venous thromboembolism in patients with grade II and III astrocytoma.
Venous Thromboembolism
IDH mutation status and the development of venous thromboembolism in astrocytoma patients.
Viremia
Acute GB virus B infection of marmosets is accompanied by mutations in the NS5A protein.
Weil Disease
[The value of isocitric dehydrogenase in the differential diagnosis between viral hepatitis and Weil's disease.]
Whooping Cough
A Functional Tricarboxylic Acid Cycle Operates during Growth of Bordetella pertussis on Amino Acid Mixtures as Sole Carbon Substrates.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
SOURCE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable).
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Hartong, D.T.; Dange, M.; McGee, T.L.; Berson, E.L.; Dryja, T.P.; Colman, R.F.
Novel insights into the contributions of isocitrate dehydrogenases to the Krebs cycle from patients with retinitis pigmentosa
Nat. Genet.
40
1230-1234
2008
Homo sapiens (O43837)
brenda
EXTERNAL LINKS (specific for EC-Number 1.1.1.41)
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
About BRENDA
Social media
Help
Survey
Download
Contribution
Legal
Curated at
Member of
